LLY

Jul 23, 2026

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from...

Eli Lilly announced positive topline results from two Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, for retatrutide, a triple hormone receptor agonist. In TRIUMPH-2, participants with obesity and type 2 diabetes lost up to 49.6 lbs, while those in TRIUMPH-3 with severe obesity and cardiovascular disease lost up to 55.8 lbs. Lilly plans to submit a BLA for retatrutide in Q1 2027.

LLY

Jul 22, 2026

Lilly confirms date and conference call for second-quarter 2026 financial results announcement

Eli Lilly and Company will announce its second-quarter 2026 financial results on August 5, 2026. A conference call will follow at 10 a.m. Eastern time, aimed at providing further details to investors and the media. The call will be accessible via a live webcast, with a replay available afterward.

LLY

Jul 9, 2026

/C O R R E C T I O N -- Eli Lilly and Company/

Eli Lilly and Company announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference, showcasing new data on Alzheimer's diagnostics and treatment, particularly focusing on P-tau217 blood tests and the efficacy of Kisunla (donanemab-azbt). The presentations will cover various aspects of Alzheimer's research, including safety and long-term treatment insights.

LLY

Jun 26, 2026

Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI

Eli Lilly has launched 'The Memory Radio Station' in Geneva, a campaign aimed at raising awareness of Alzheimer's disease and its early symptoms. This initiative invites the public to share personal memories and utilize generative AI to visualize them. The campaign will travel across multiple European countries, highlighting the importance of recognizing memory changes early.

LLY

Jun 26, 2026

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Eli Lilly's Jaypirca (pirtobrutinib) received a positive opinion from the CHMP for treating adults with chronic lymphocytic leukemia (CLL) across all therapy lines. This recommendation is based on promising results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials. The decision is now pending final action from the European Commission, expected in one to two months.

LLY

Jun 25, 2026

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management Eli Lilly and Company (NYSE: LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under...

Eli Lilly has announced the Medicare GLP-1 Bridge program, effective July 1, 2026, which will allow eligible Medicare Part D patients to access its obesity treatments, Foundayo (orforglipron) and Zepbound (tirzepatide), for $50 per month. This program marks a significant milestone in the coverage of weight management medications under Medicare, addressing the needs of older adults facing obesity. Both medications have shown promising results in clinical trials, particularly for patients aged 65 and older.

LLY

Jun 24, 2026

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Eli Lilly has completed its acquisition of Centessa Pharmaceuticals, focusing on developing orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. Lilly's executive emphasizes the importance of the orexin system in brain health and the urgent need for effective treatments. The acquisition aims to leverage Centessa's clinical portfolio to address significant unmet needs in this area.

LLY

Jun 22, 2026

Lilly declares third-quarter 2026 dividend

Eli Lilly and Company has announced a dividend of $1.73 per share for the third quarter of 2026. This dividend is set to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. The company emphasizes its commitment to advancing healthcare solutions and ensuring accessibility to its medicines.

LLY

Jun 19, 2026

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

The 5W AI Visibility Index 2026 reveals that Eli Lilly and Novo Nordisk dominate AI citation share despite not being the highest spenders on direct-to-consumer advertising. The report indicates that consumer research significantly influences drug visibility, with a notable disconnect between ad spend and AI citation outcomes. This trend suggests a shift in how patients seek information about medications.

LLY

Jun 14, 2026

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent...

Eli Lilly has announced positive results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), which showed a 45% reduction in the risk of disease progression or death when added to a venetoclax and rituximab regimen in patients with previously treated CLL/SLL. This trial is notable as it is the first to demonstrate superiority in a venetoclax-containing treatment regimen. The findings will be presented at the 2026 EHA Annual Meeting, highlighting the potential of Jaypirca in shifting treatment standards in CLL. Lilly plans to submit these results to global regulatory authorities for label expansion.

LLY

Jun 13, 2026

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Eli Lilly announced promising initial data from the Phase 1 AJX-101 study of its type II JAK2 inhibitor, AJ1-11095, for myelofibrosis patients previously treated with type I JAK2 inhibitors. The results indicate a favorable safety profile and significant clinical activity, including reductions in spleen size and symptom improvement. This data will be presented at the 2026 EHA Annual Meeting.

LLY

Jun 10, 2026

Zepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable Eli Lilly and Company (NYSE: LLY) today announced that basketball legend and cultural icon Shaquille O'Neal is sharing his personal experience with...

Eli Lilly and Company announced a national campaign featuring Shaquille O'Neal to raise awareness about moderate obstructive sleep apnea (OSA). O'Neal candidly discusses his struggles with the condition and the transformative impact of Zepbound (tirzepatide) on his health journey. The campaign aims to inform the public about the symptoms of OSA and encourage individuals to consult their doctors for proper diagnosis and treatment. Zepbound is highlighted as a key treatment option that should be combined with lifestyle changes.

LLY

Jun 9, 2026

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

Convatec and the Lilly Foundation have announced a $5 million commitment to Partners In Health. This funding aims to enhance care for non-communicable diseases and chronic conditions. The partnership reflects a significant investment in improving healthcare outcomes for affected populations.

LLY

Jun 9, 2026

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has received FDA approval for a maintenance dose of one injection every eight weeks for patients aged 12 and older with moderate-to-severe atopic dermatitis. This new regimen allows for as few as six injections per year, enhancing patient convenience and reducing treatment burden. The approval is based on positive long-term clinical trial data.

LLY

Jun 8, 2026

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from three Phase 3 trials in the ACHIEVE...

Eli Lilly announced that its oral GLP-1 treatment, Foundayo (orforglipron), showed superior efficacy in controlling blood sugar and reducing weight in three Phase 3 clinical trials. The trials demonstrated that Foundayo outperformed oral semaglutide and achieved significant improvements in A1C levels and weight loss among adults with type 2 diabetes. Lilly plans to submit Foundayo for FDA approval by the end of the second quarter, aiming to position it as a frontline therapy option. Despite promising results, some gastrointestinal adverse events were noted, which may impact patient tolerability.

LLY

Jun 7, 2026

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight...

Eli Lilly and Company announced significant findings from the ATTAIN-1 and ATTAIN-2 trials, showcasing that their oral GLP-1 drug, Foundayo (orforglipron), contributes to substantial weight loss in women at all stages of menopause. Women treated with Foundayo reported up to 30.4 lbs of weight loss in perimenopausal and 28.2 lbs in post-menopausal participants. Additionally, reductions in waist circumference were noted, which is linked to a decrease in abdominal fat and cardiometabolic risks. However, potential serious side effects, including thyroid tumors, remain a concern.

LLY

Jun 6, 2026

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer...

Eli Lilly's investigational drug retatrutide has shown promising results in Phase 3 trials, TRIUMPH-1 and TRANSCEND-T2D-1, demonstrating significant weight loss and improvements in conditions associated with obesity. Participants lost an average of 70.3 lbs over 80 weeks, with many achieving a BMI under 30 and substantial reductions in A1C levels. The treatment offered positive outcomes for knee osteoarthritis pain and obstructive sleep apnea. While the drug exhibited efficacy, it was linked with some mild to moderate adverse events, including nausea and diarrhea.

LLY

Jun 2, 2026

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Eli Lilly will showcase its hematology portfolio at the 2026 EHA Annual Meeting, featuring results from the Phase 3 BRUIN CLL-322 study on pirtobrutinib. Ajax Therapeutics will present data on its type II JAK2 inhibitor for myelofibrosis, while Kelonia Therapeutics will share findings on its CAR-T therapy for multiple myeloma. These presentations highlight Lilly's strategic acquisitions and ongoing commitment to hematology.

LLY

Jun 1, 2026

Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Eli Lilly announced that Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death in early-stage RET fusion-positive lung cancer patients in the Phase 3 LIBRETTO-432 trial. The study's results are set to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting. This trial highlights the importance of comprehensive biomarker testing and may establish a new standard of care for this patient population.

LLY

May 31, 2026

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Eli Lilly's Phase 3 LIBRETTO-432 trial showed that Retevmo (selpercatinib) significantly reduces the risk of disease recurrence or death by 83% in early-stage RET fusion-positive lung cancer patients. The trial met its primary endpoint, demonstrating improved event-free survival compared to placebo. These findings may lead to changes in treatment practices for this patient population.

LLY

May 28, 2026

Foundayo and Zepbound now covered for millions of Americans

Eli Lilly announced that CVS Caremark will begin covering Foundayo on June 1 and resume coverage for Zepbound by October 1. This development allows millions of Americans to access these FDA-approved obesity treatments through their insurance. Eligible patients may pay as little as $25 a month for their medications, significantly improving access to effective obesity care.

LLY

May 28, 2026

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in...

Eli Lilly will present new data on its cardiometabolic portfolio, including findings for Foundayo and retatrutide, at the American Diabetes Association's 86th Scientific Sessions. Phase 3 results indicated Foundayo, an oral GLP-1, significantly outperformed traditional medications in managing type 2 diabetes. Additionally, retatrutide showed promising efficacy in treating obesity and diabetes-related conditions. These developments aim to enhance patient choice and redefine treatment standards in diabetes and obesity care.

LLY

May 27, 2026

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

Eli Lilly and Company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, the executive vice president, will engage in a fireside chat. A live audio webcast will be available, along with a replay for 90 days on Lilly's investor website.

LLY

May 26, 2026

Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech...

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of three companies: Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, aimed at enhancing its infectious disease portfolio. These acquisitions focus on developing vaccines for viral and bacterial pathogens, addressing serious long-term health risks. Notably, Curevo's shingles vaccine candidate is expected to improve vaccination rates by reducing side effects. Lilly's strategy emphasizes disease prevention at the source rather than managing consequences, reinforcing its commitment to public health.

LLY

May 25, 2026

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

Eli Lilly announced positive results from the Phase 1b Heart-2 trial for VERVE-102, a base editing medicine aimed at lowering PCSK9 and LDL-C levels. The trial showed dose-dependent reductions in PCSK9 by up to 88% and LDL-C by up to 62%, with effects lasting up to 18 months. Lilly plans to start a Phase 2 study by year-end.

LLY

May 22, 2026

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

Eli Lilly and Company will present its oncology portfolio at the 2026 ASCO Annual Meeting, showcasing advancements in treatments for various cancers. Key highlights include the Phase 3 LIBRETTO-432 study of Retevmo for RET fusion-positive NSCLC and an investigator-initiated study of Verzenio in dedifferentiated liposarcoma. Additional presentations will cover new data from Kelonia Therapeutics and investigational therapies targeting Nectin-4.

LLY

May 21, 2026

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session...

Eli Lilly will present key findings from its oncology portfolio at the 2026 ASCO Annual Meeting, including results from the Phase 3 LIBRETTO-432 study of Retevmo in RET fusion-positive NSCLC. The company will also showcase an investigator-initiated study of Verzenio in dedifferentiated liposarcoma and data from its acquisition of Kelonia Therapeutics. These presentations highlight Lilly's commitment to advancing cancer therapies.

LLY

May 21, 2026

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight...

Eli Lilly's TRIUMPH-1 trial results indicate that retatrutide, a triple hormone receptor agonist, significantly aids weight loss in participants with obesity or overweight. Over 80 weeks, those on the 12 mg dose lost an average of 70.3 lbs, with 45.3% achieving at least 30% weight reduction. Improvements in cardiometabolic health measures were also observed. While adverse events were reported, the treatment is seen as a promising option against obesity, with ongoing evaluations planned in future clinical trials.

LLY

May 18, 2026

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference

Eli Lilly and Company will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D., Ph.D., will engage in a fireside chat during the event. A live audio webcast will be available on Lilly's investor website, with a replay accessible for 90 days.

LLY

May 16, 2026

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE: LLY) and Musco Lighting, has opened three new multi-sport community...

Eli Lilly and Company, in collaboration with the Caitlin Clark Foundation and Musco Lighting, has inaugurated three multi-sport community courts in Indianapolis. This initiative aims to provide year-round access to high-quality sports facilities for youth as part of Lilly's 150th anniversary. The courts, which include locations at local schools and a public park, will support physical activity and community engagement for families and young people. This partnership underscores Lilly's commitment to enhancing community health beyond just medicine.

LLY

May 14, 2026

Lilly and UNICEF collaborate to give millions of children a healthier start Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care ...

Eli Lilly and UNICEF USA have announced a six-year collaboration focused on improving non-communicable disease (NCD) prevention and care for children in low- and middle-income countries. Lilly is committing $50 million to bolster primary healthcare systems, which will enhance the detection and management of NCDs among children and adolescents. The initiative aims to reach over 30 million young people and caregivers and is designed to integrate prevention and care into routine health services. This effort coincides with Lilly's 150th anniversary and aligns with its broader 30x30 initiative to enhance healthcare access in underserved areas.

LLY

May 13, 2026

Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

Eli Lilly announced positive results from two late-phase trials, ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, demonstrating that participants maintained significant weight loss after switching from higher doses of injectable incretin therapy to either Foundayo or lower-dose Zepbound. The findings, presented at the European Congress on Obesity, highlight the potential of these medications for long-term weight maintenance. Both trials met their primary and secondary endpoints, reinforcing Lilly's commitment to obesity treatment.

LLY

May 12, 2026

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg...

Eli Lilly announced positive results from two late-phase trials, ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, showing that participants maintained significant weight loss after switching from higher doses of injectable incretin therapy to either Foundayo or lower-dose Zepbound. The trials demonstrated that both medications effectively support long-term weight maintenance, addressing a critical challenge in obesity treatment. Findings were presented at the 33rd European Congress on Obesity and published in leading medical journals.

LLY

May 12, 2026

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

Eli Lilly and Company has launched an initiative to support nutritious food distribution as part of its 150th anniversary. The company will provide charitable support to community organizations, enabling the distribution of approximately 500,000 meals across 15 communities. Additionally, Lilly's support will help establish cold storage infrastructure at 150 food pantries, facilitating the delivery of five million protein-rich meals annually.

LLY

May 11, 2026

The Next Generation of the GLP-1 Revolution Is Already Underway

The article discusses the rapid evolution of GLP-1 receptor agonists in treating obesity and type 2 diabetes, highlighting SureNano Science's GEP-44 as a promising next-generation therapy. With the global GLP-1 market expected to grow significantly, innovations in drug delivery and efficacy are becoming critical. Eli Lilly's recent FDA approval of Foundayo marks a notable advancement in this field.

LLY

May 6, 2026

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

Eli Lilly and Company has announced an additional $4.5 billion investment in its Indiana manufacturing sites, bringing its total commitments since 2020 to over $21 billion. This investment includes the opening of the Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility. The expansion aims to meet the anticipated demand for advanced therapies and will support both clinical and commercial production.

LLY

May 5, 2026

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

Eli Lilly's Omvoh (mirikizumab-mrkz) has demonstrated durable disease clearance in ulcerative colitis patients over four years of treatment, with 63.5% of those achieving clearance at one year maintaining it. This marks a significant milestone as it is the first IL-23p19 inhibitor to achieve such results. The findings will be presented at Digestive Disease Week 2026.

LLY

May 4, 2026

Lilly declares second-quarter 2026 dividend

Eli Lilly and Company has announced a dividend of $1.73 per share for the second quarter of 2026, payable on June 10, 2026, to shareholders of record by May 15, 2026. This decision highlights the company's ongoing commitment to returning value to its shareholders, despite acknowledging potential risks in its business operations and research activities.

LLY

Apr 30, 2026

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

Eli Lilly reported a strong first quarter in 2026 with a 56% increase in revenue, driven by significant growth in key products like Mounjaro and Zepbound. The company also received FDA approval for Foundayo, enhancing access to GLP-1 medications. Despite challenges such as lower realized prices and increased R&D expenses, Lilly raised its full-year revenue guidance by $2 billion.

LLY

Apr 27, 2026

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ( Ajax ), a biopharmaceutical company developing next generation JAK inhibitors for...

Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics, a biopharmaceutical firm focused on developing next-generation JAK inhibitors for myeloproliferative neoplasms. Ajax's lead asset, AJ1-11095, is a Type II JAK2 inhibitor currently in Phase 1 trials, showing promise for providing patients with improved disease control. The acquisition, which could amount to $2.3 billion, is aimed at enhancing Lilly's capabilities in blood cancer treatment. The closure of the deal is contingent on regulatory approvals and other customary conditions, with potential risks surrounding its success.

LLY

Apr 20, 2026

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ( Kelonia ), a clinical-stage biotechnology company pioneering in vivo gene...

Eli Lilly has announced its acquisition of Kelonia Therapeutics, a company specializing in in vivo CAR-T cell therapies. This acquisition is aimed at enhancing Lilly's capabilities in genetic medicine, particularly with Kelonia's lead program, KLN-1010, which is in Phase 1 trials for relapsed/refractory multiple myeloma. The deal is valued at up to $7 billion, including an upfront payment of $3.25 billion, with additional payments based on clinical milestones. The transaction is expected to close in the second half of 2026, pending regulatory approvals.

LLY

Apr 17, 2026

Lilly confirms date and conference call for first-quarter 2026 financial results announcement

Eli Lilly and Company will announce its first-quarter 2026 financial results on April 30, 2026. A conference call will follow at 10 a.m. Eastern time, providing details on the company's performance. The call will be accessible via a live webcast, with a replay available afterward.

LLY

Apr 16, 2026

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

The Phase 3 ACHIEVE-4 trial of Foundayo (orforglipron) has shown positive results, meeting its primary objective of non-inferiority compared to insulin glargine. The trial revealed a significant reduction in major adverse cardiovascular events and all-cause mortality. Eli Lilly plans to submit Foundayo for FDA approval for treating type 2 diabetes by the end of Q2 2026.

LLY

Apr 14, 2026

Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company

Eli Lilly and Company has acquired CrossBridge Bio, a portfolio company of Linden Lake Labs. This acquisition is seen as a strategic move to enhance Lilly's capabilities and expand its product offerings. The deal reflects Lilly's commitment to growth and innovation in the biopharma sector.

LLY

Apr 13, 2026

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 trial, showing that the addition of Jaypirca (pirtobrutinib) to a venetoclax regimen significantly improved progression-free survival in patients with relapsed or refractory CLL/SLL. The study met its primary endpoint and demonstrated consistent results across subgroups. Overall survival data is still maturing, but trending positively. Detailed results will be presented at a medical congress and submitted for regulatory review.

LLY

Apr 10, 2026

LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LifeMD has announced the availability of Foundayo (orforglipron), a new oral GLP-1 medication for weight management, developed by Eli Lilly. Approved by the FDA on April 1, 2026, Foundayo is now accessible to eligible patients through LifeMD's weight management program. The medication is priced at $149 per month, with potential savings for insured patients. This addition enhances LifeMD's offerings in clinically guided weight management care.

LLY

Apr 9, 2026

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

Eli Lilly has announced the availability of Foundayo™ (orforglipron), an oral GLP-1 medication for weight loss, following FDA approval. This once-daily pill can be taken without food or water restrictions and is accessible through LillyDirect and telehealth providers. Clinical trials demonstrated an average weight loss of 27 pounds at the highest dose, but it carries potential risks, including thyroid tumors.

LLY

Apr 9, 2026

Amazon Pharmacy to Offer Eli Lilly and Company’s New GLP-1 Pill Foundayo via Same-Day Delivery

Amazon Pharmacy has begun offering Eli Lilly's newly approved GLP-1 medication, Foundayo, which is designed for adults dealing with obesity or weight-related health issues. Customers can order the medication with a valid prescription and benefit from real-time availability and transparent pricing. The service includes same-day delivery to enhance accessibility for patients.

LLY

Apr 9, 2026

Foundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos. Eli Lilly and Company (NYSE: LLY) ha anunciado hoy que Foundayo™ (orforglipron) ya está disponible para adultos con obesidad o con sobrepeso, que...

Eli Lilly and Company has announced the availability of Foundayo™ (orforglipron) in the U.S. for adults with obesity or overweight. Approved by the FDA, this GLP-1 medication is unique as it is taken orally once daily without dietary restrictions, starting at a cost of $25 per month for insured patients. Clinical trials demonstrated an average weight loss of 27 pounds, showcasing its effectiveness. However, the medication is accompanied by potential serious side effects, including the risk of thyroid tumors and pancreatitis.

LLY

Apr 9, 2026

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GoodRx has partnered with Eli Lilly to enhance access to the newly FDA-approved oral GLP-1 medication, Foundayo. Self-pay patients can obtain Foundayo through GoodRx at a starting price of $149 per month. This initiative aims to provide transparent pricing and improve medication accessibility across more than 70,000 pharmacies nationwide.

LLY

Apr 9, 2026

Weight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect

Weight Watchers has announced the availability of Eli Lilly's new oral GLP-1 medication, Foundayo® (orforglipron), through its Med+ offering. This FDA-approved treatment provides a once-daily, injection-free option for adults with obesity or weight-related medical issues. Members will receive clinical support and access to the GLP-1 Success program to enhance their treatment experience.

LLY

Apr 2, 2026

La FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o aguaUSA - españolUSA - English

Eli Lilly has received FDA approval for Foundayo (orforglipron), a new oral medication for adults with obesity or overweight. In clinical trials, patients lost an average of 27 pounds, demonstrating significant efficacy. Foundayo will be available through LillyDirect for home delivery, with various pricing options. The drug aims to provide a flexible treatment option for individuals managing obesity.

LLY

Apr 1, 2026

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

Eli Lilly's Foundayo (orforglipron) has received FDA approval as the first oral GLP-1 medication for weight loss, allowing flexible dosing without food or water restrictions. In clinical trials, participants lost an average of 27 pounds, demonstrating its efficacy. Foundayo will be available through LillyDirect, with pricing starting at $25 per month for insured patients.

LLY

Mar 31, 2026

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for...

Eli Lilly and Company announced its agreement to acquire Centessa Pharmaceuticals, which specializes in a new class of medicines targeting sleep-wake disorders. The acquisition focuses on advancing Centessa's OX2R agonist pipeline, including the promising candidate cleminorexton for conditions like narcolepsy. This deal could enhance Lilly's capabilities in neuroscience and expedite the development of innovative treatments for numerous neurological disorders. However, the transaction is subject to regulatory and shareholder approval, and contingent payments based on milestones are not guaranteed.

LLY

Mar 30, 2026

Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising long-term results in the ADlong Phase 3b study, demonstrating durable disease control for patients with moderate-to-severe atopic dermatitis. Nearly all patients achieved significant skin improvement over four years, with many experiencing itch relief and maintaining results without topical corticosteroids. The study's findings highlight the potential of EBGLYSS to transform treatment approaches for this condition.

LLY

Mar 30, 2026

Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

Eli Lilly presented positive results from the TOGETHER-PsA Phase 3b trial at the AAD Annual Meeting, demonstrating that the combination of Taltz and Zepbound significantly improves outcomes for adults with psoriatic arthritis and obesity. The treatment showed early efficacy in reducing disease activity and enhancing quality of life. Adverse events were generally mild to moderate, consistent with known safety profiles.

LLY

Mar 28, 2026

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the...

Eli Lilly presented positive results from the TOGETHER-PsA Phase 3b trial, demonstrating that the combination of Taltz and Zepbound is more effective than Taltz monotherapy for treating adults with psoriatic arthritis and obesity. Patients on the combination therapy showed notable reductions in disease activity and improvements in various health metrics within just four weeks. The findings suggest a shift in treatment strategies for managing these interlinked conditions, although mild to moderate adverse events were noted. Full results were shared at the AAD Annual Meeting and published in a medical journal.

LLY

Mar 27, 2026

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) demonstrated long-term efficacy in patients with moderate-to-severe atopic dermatitis, achieving significant skin improvement and itch relief for up to four years. The Phase 3b ADlong study revealed that a majority of patients maintained results without the need for topical corticosteroids. The treatment's safety profile remained consistent, with no new safety signals identified.

LLY

Mar 19, 2026

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and ...

Eli Lilly announced positive results from its Phase 3 trial of retatrutide, a novel triple agonist for type 2 diabetes. The trial showed significant reductions in A1C levels, averaging between 1.7% and 2.0%, and substantial weight loss of up to 36.6 lbs over 40 weeks. Additionally, retatrutide met both primary and secondary endpoints, outperforming placebo. While adverse events were reported, they are consistent with similar treatments and generally resolved during the study.

LLY

Mar 16, 2026

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of...

Eli Lilly announced positive topline results from the Phase 3 ADorable-1 trial of EBGLYSS (lebrikizumab-lbkz) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis. The trial demonstrated that 63% of participants achieved significant skin improvement, while 44% experienced nearly clear skin. EBGLYSS displayed a favorable safety profile consistent with earlier studies, addressing a critical need for effective treatments in younger patients suffering from atopic dermatitis. Lilly plans to submit these promising results to regulators for potential label updates.

LLY

Mar 5, 2026

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients

Eli Lilly has launched the Employer Connect platform to improve access to obesity treatment in the U.S. The platform allows employers to work with independent program administrators to create tailored benefit designs that lower costs for employees. Zepbound, an obesity management medication, is available through this platform at a discounted price, promoting broader access to effective treatment options.

LLY

Feb 27, 2026

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

The CHMP has recommended Olumiant (baricitinib) for adolescents with severe alopecia areata in the EU, based on positive results from the Phase 3 BRAVE-AA-PEDS study. The study showed that 42% of participants achieved over 80% scalp hair coverage at 36 weeks. Lilly is also seeking approval in the U.S., with a decision expected in 2026.

LLY

Feb 26, 2026

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

Eli Lilly's orforglipron demonstrated superior efficacy in controlling blood sugar and promoting weight loss compared to oral semaglutide in the Phase 3 ACHIEVE-3 trial. The study involved 1,698 participants and showed significant improvements in A1C levels and weight loss. Orforglipron can be taken without food or water restrictions, making it a potentially more convenient option for patients. Regulatory submissions for orforglipron are ongoing in over 40 countries, with U.S. action expected in 2026.

LLY

Feb 26, 2026

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

Eli Lilly's orforglipron demonstrated superior efficacy in controlling blood sugar and promoting weight loss compared to oral semaglutide in the Phase 3 ACHIEVE-3 trial. The study involved 1,698 participants and showed significant improvements in A1C levels and weight loss. Orforglipron's convenience of administration without food or water restrictions may enhance patient adherence. Regulatory submissions for the drug are ongoing in over 40 countries, with a U.S. action expected in Q2 2026.

LLY

Feb 23, 2026

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

Eli Lilly has announced the FDA's approval for a label expansion of Zepbound (tirzepatide), now available in a multi-dose KwikPen. This new delivery method allows patients to receive a full month of treatment in one device, enhancing accessibility. Zepbound is recognized as the leading injectable obesity management medication, with patients achieving significant weight loss. The medication is available through LillyDirect at a starting price of $299 per month.

LLY

Feb 19, 2026

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three...

Eli Lilly's Omvoh (mirikizumab-mrkz) has shown impressive long-term efficacy in treating Crohn's disease, with over 90% of patients maintaining steroid-free remission for three years. The recent data, presented at the ECCO Congress, also highlighted significantly low rates of surgery and hospitalization among Omvoh-treated patients. This makes Omvoh the only IL-23p19 inhibitor to demonstrate strong and durable effectiveness. Clinical experts express confidence in Omvoh's long-term outcomes, marking a potential shift in the treatment landscape for inflammatory bowel disease.

LLY

Feb 18, 2026

Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

Eli Lilly's TOGETHER-PsO Phase 3b trial demonstrated that the combination of Taltz and Zepbound significantly outperformed Taltz monotherapy in achieving complete skin clearance and weight loss in adults with psoriasis and obesity. The study found that 27.1% of participants on the combination therapy achieved PASI 100 and at least 10% weight loss, compared to 5.8% in the monotherapy group. This trial marks a significant advancement in treating patients with both conditions simultaneously.

LLY

Feb 18, 2026

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete ...

Eli Lilly's TOGETHER-PsO study demonstrated that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) significantly outperformed Taltz alone in achieving complete skin clearance and weight loss in adults with psoriasis and obesity. At 36 weeks, 27.1% of participants on the combination therapy reached PASI 100, compared to 5.8% on Taltz monotherapy. The study highlights the importance of addressing both psoriasis and obesity simultaneously.

LLY

Feb 17, 2026

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

Scribe Therapeutics has successfully achieved a second milestone in its collaboration with Eli Lilly, focusing on in vivo CRISPR-based genetic medicines for neurological and neuromuscular disorders. This milestone underscores the effectiveness of Scribe's X-Editor technology and the companies' commitment to innovation in genetic medicine. The collaboration is set to yield significant financial benefits, with Scribe eligible for over $1.5 billion in milestone payments.

LLY

Feb 16, 2026

Lilly to participate in TD Cowen's 46th Annual Health Care Conference

Eli Lilly and Company will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. CFO Lucas Montarce will engage in a fireside chat, which will be available via live audio webcast. The event reflects Lilly's ongoing commitment to sharing insights and advancements in healthcare.

LLY

Feb 16, 2026

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Eli Lilly announced positive topline results from the Phase 3 LIBRETTO-432 trial, showing Retevmo (selpercatinib) significantly improves event-free survival in early-stage RET fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, reinforcing the value of genomic testing. Overall survival data are still immature, but safety profiles align with previous studies.

LLY

Feb 16, 2026

USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company The United States Olympic & Paralympic Committee (USOPC) today announced the Team USA Athlete Recovery Program in partnership with Lilly, reinforcing ...

The United States Olympic & Paralympic Committee (USOPC) has announced the Team USA Athlete Recovery Program in partnership with Eli Lilly, aimed at enhancing athlete health and recovery beyond competition. Lilly will serve as the presenting partner, supporting access to vital rehabilitation resources for athletes through major upcoming events like the Milano Cortina 2026 and LA28 Olympic Games. Following the program's successful pilot in 2024, which assisted athletes in earning four medals at Paris 2024, the USOPC plans to expand its reach to a broader network of Team USA athletes over the next three years.

LLY

Feb 9, 2026

Lilly to acquire Orna Therapeutics to advance cell therapies

Eli Lilly has announced its acquisition of Orna Therapeutics, which specializes in in vivo CAR-T therapies. This acquisition aims to enhance Lilly's capabilities in genetic medicine and address B cell-driven autoimmune diseases. Orna's innovative circular RNA technology is expected to provide durable therapeutic solutions. The deal could be worth up to $2.4 billion, contingent on clinical milestones.

LLY

Feb 9, 2026

Lilly to acquire Orna Therapeutics to advance cell therapies Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced ...

Eli Lilly has announced its acquisition of Orna Therapeutics to enhance its capabilities in cell therapies. Orna's innovative circular RNA technology aims to develop in vivo CAR-T therapies for B cell-driven autoimmune diseases. The deal, potentially worth up to $2.4 billion, reflects Lilly's commitment to advancing genetic medicine and improving patient care.

LLY

Feb 4, 2026

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

Eli Lilly and Company reported a robust financial performance for Q4 2025, with a 43% increase in worldwide revenue, driven by strong demand for key products like Mounjaro and Zepbound. The company also provided optimistic financial guidance for 2026, highlighting its expanded manufacturing capacity and ongoing product launches. However, challenges such as lower realized prices and increased expenses were noted.

LLY

Jan 30, 2026

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

Eli Lilly has announced a $3.5 billion investment in a new manufacturing facility in Lehigh Valley, Pennsylvania, aimed at producing next-generation weight-loss therapies, including retatrutide. The facility is expected to create over 2,800 jobs, including 850 high-value positions. Construction is set to begin in 2026, with operations starting in 2031. This investment is part of Lilly's broader strategy to enhance domestic medicine production.

LLY

Jan 22, 2026

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

Eli Lilly and Company will announce its fourth-quarter 2025 financial results on February 4, 2026. A conference call will follow at 10 a.m. Eastern time, allowing investors and the media to discuss the company's financial performance. The event will be accessible via a live webcast, with a replay available afterward.

LLY

Jan 20, 2026

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Eli Lilly has received Breakthrough Therapy designation from the FDA for sofetabart mipitecan, aimed at treating adult patients with platinum-resistant ovarian cancer. This designation is based on encouraging preliminary results from Phase 1 trials, which suggest significant improvement over current therapies. The company has initiated a Phase 3 trial to further investigate the drug's efficacy.

LLY

Jan 9, 2026

Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

Eli Lilly announced positive results from the TOGETHER-PsA Phase 3b trial, which evaluated the combination of Taltz and Zepbound in adults with active psoriatic arthritis and obesity. The study met its primary endpoint, showing a significant improvement in PsA activity and weight reduction compared to Taltz alone. This trial represents a pioneering approach to treating patients with both conditions simultaneously.

LLY

Jan 8, 2026

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to...

Eli Lilly's TOGETHER-PsA trial demonstrated that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improved outcomes for adults with active psoriatic arthritis and obesity. The study met its primary endpoint of a 50% improvement in PsA activity and showed a 64% increase in patients achieving ACR50 compared to Taltz alone. This trial is notable for being the first to evaluate an incretin therapy alongside a PsA biologic, highlighting a potential shift in treatment paradigms.

LLY

Jan 7, 2026

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on...

Eli Lilly and Company has announced its plans to acquire Ventyx Biosciences to enhance its portfolio of oral therapies aimed at inflammatory-mediated diseases. The deal is valued at approximately $1.2 billion, with Lilly offering $14.00 per share for all outstanding shares of Ventyx. This acquisition is expected to close in the first half of 2026, pending stockholder and regulatory approvals. Ventyx's clinical pipeline includes NLRP3 inhibitors with significant potential for treating conditions like chronic inflammation, neurodegenerative diseases, and cardiometabolic disorders.

LLY

Dec 18, 2025

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron,...

Eli Lilly announced positive topline results from the Phase 3 ATTAIN-MAINTAIN trial, demonstrating that orforglipron, an oral GLP-1 receptor agonist, effectively maintained weight loss for participants previously treated with Wegovy or Zepbound. On average, those switching to orforglipron retained almost all their previously lost weight after 52 weeks, showing promising efficacy compared to placebo. The investigational drug is being evaluated for its potential to offer a convenient oral option for individuals with obesity, with a new drug application submitted to the FDA for regulatory review.

LLY

Dec 16, 2025

Lilly to participate in J.P. Morgan Healthcare Conference

Eli Lilly and Company will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2025. CEO David A. Ricks will host a fireside chat on January 13 at 5:15 p.m. Eastern time. A live audio webcast will be available, along with a replay for 90 days on Lilly's investor website.

LLY

Dec 12, 2025

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

Eli Lilly announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for ER+, HER2- advanced breast cancer. The study showed that imlunestrant as monotherapy improved median overall survival by 11.4 months compared to endocrine therapy. Additionally, the combination with abemaciclib achieved a median progression-free survival of 10.9 months and delayed time to chemotherapy significantly. These findings will be presented at the San Antonio Breast Cancer Symposium.

LLY

Dec 11, 2025

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Eli Lilly announced positive results from the Phase 3 TRIUMPH-4 trial of retatrutide, showing an average weight loss of 28.7% and significant pain relief in knee osteoarthritis patients. The trial involved 445 participants and met all primary and secondary endpoints. Retatrutide is a triple hormone receptor agonist, and further trials are planned to assess its efficacy in obesity and related conditions.

LLY

Dec 9, 2025

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

Eli Lilly announced a $6 billion investment in a new manufacturing facility in Huntsville, Alabama, aimed at producing small molecule synthetic and peptide medicines, including orforglipron. This facility will create 3,450 jobs and is part of Lilly's strategy to enhance domestic production capabilities. Construction is set to begin in 2026, with completion expected in 2032.

LLY

Dec 9, 2025

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

Eli Lilly and Company has completed its tender offer for Adverum Biotechnologies, acquiring approximately 64% of its shares. The acquisition is expected to enhance Lilly's capabilities in gene therapy, particularly for age-related conditions. The transaction is set to be finalized on December 9, 2025, following the satisfaction of all conditions.

LLY

Dec 9, 2025

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

Eli Lilly announced that Jaypirca (pirtobrutinib) significantly improved progression-free survival in treatment-naïve CLL/SLL patients, reducing the risk of progression or death by 80% compared to chemoimmunotherapy. The results from the Phase 3 BRUIN CLL-313 trial will be presented at the 2025 ASH Annual Meeting and published in the Journal of Clinical Oncology. The findings highlight the potential of pirtobrutinib as a treatment option for newly diagnosed patients.

LLY

Dec 8, 2025

Lilly declares first-quarter 2026 dividend

Eli Lilly and Company has announced a dividend of $1.73 per share for the first quarter of 2026. This dividend will be payable on March 10, 2026, to shareholders who are on record by February 13, 2026. The announcement reflects Lilly's ongoing commitment to delivering value to its shareholders while continuing its mission in healthcare innovation.

LLY

Dec 8, 2025

Carolyn Bertozzi returns to Lilly board of directors

Eli Lilly and Company has re-elected Carolyn R. Bertozzi, Ph.D., to its board of directors, effective December 8, 2025. Bertozzi, a Nobel Prize-winning chemist, will contribute to the Science and Technology and Ethics and Compliance committees. Her previous tenure from 2017 to 2021 and her expertise in developing targeted cancer therapies are expected to enhance Lilly's ongoing efforts in oncology and immunology.

LLY

Dec 8, 2025

Lilly’s Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly's Phase 3 BRUIN CLL-314 trial demonstrated that Jaypirca (pirtobrutinib) met its primary endpoint of non-inferiority in overall response rate compared to Imbruvica (ibrutinib). Pirtobrutinib showed an 87% response rate versus 78.5% for ibrutinib. Additionally, there were promising trends in progression-free survival, particularly in treatment-naïve patients. The results will be presented at the upcoming ASH Annual Meeting.

LLY

Dec 7, 2025

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly announced that Jaypirca (pirtobrutinib) met its primary endpoint of non-inferiority in the Phase 3 BRUIN CLL-314 study against Imbruvica (ibrutinib) for chronic lymphocytic leukemia. Pirtobrutinib demonstrated a higher overall response rate of 87.0% compared to 78.5% for ibrutinib. Additionally, it showed a favorable trend in progression-free survival, particularly in treatment-naïve patients. The results will be presented at the upcoming American Society of Hematology Annual Meeting.

LLY

Dec 3, 2025

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

The U.S. FDA has approved an expanded indication for Lilly's Jaypirca (pirtobrutinib) for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a covalent BTK inhibitor. This approval is based on the BRUIN CLL-321 trial, which is the only randomized Phase 3 study in this patient population. The expanded label allows for earlier treatment and converts the previous accelerated approval to a traditional one.

LLY

Nov 24, 2025

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

Eli Lilly announced that it will present updated results from key clinical trials at the 2025 San Antonio Breast Cancer Symposium. Highlights include findings from the Phase 3 EMBER-3 trial for Inluriyo and subgroup analyses from the Phase 3 monarchE trial. Lilly aims to demonstrate progress in treating hormone receptor-positive breast cancer, a prevalent form of the disease.

LLY

Nov 24, 2025

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

Eli Lilly announced that data from two Phase 3 studies of Jaypirca (pirtobrutinib) will be presented at the upcoming ASH Annual Meeting. The studies include the BRUIN CLL-314, a head-to-head comparison with Imbruvica, and BRUIN CLL-313, both focusing on treatment-naïve CLL/SLL patients. These presentations highlight the drug's potential in treating B-cell malignancies.

LLY

Nov 19, 2025

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia

Eli Lilly and Company has announced plans to open a new Lilly Gateway Labs site in Philadelphia, aimed at supporting early-stage biotech companies. The site will provide 44,000 square feet of lab space and strategic scientific engagement. This expansion is part of Lilly's strategy to enhance its presence in key life sciences innovation hubs across the U.S.

LLY

Nov 18, 2025

Lilly to participate in Citi's 2025 Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice...

Eli Lilly and Company (NYSE: LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Executive Vice President Ilya Yuffa will engage in a fireside chat during the event, scheduled for 10:30 a.m. Eastern time. Investors can access a live audio webcast through Lilly's investor website, with a replay available for 90 days following the conference.

LLY

Nov 10, 2025

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping ...

Tan France, in partnership with Lilly, has launched the Changing the Thread Collection to combat obesity bias by using clothing as a medium for personal stories. This innovative campaign aims to educate the public about obesity as a chronic disease while promoting a cultural shift toward understanding and acceptance. Zepbound, an injectable treatment for obesity, is central to this initiative, which combines storytelling with a medical solution to support individuals on their weight loss journeys. The collection seeks to empower those living with obesity to express their resilience and challenge societal misconceptions.

LLY

Nov 6, 2025

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

Eli Lilly has announced the appointment of two new Executive Committee members, Carole Ho and Adrienne Brown, to enhance its leadership team. Ho will lead Lilly Neuroscience, while Brown will oversee Lilly Immunology. The company aims to accelerate its ambitious pipeline and improve patient access to medicines. Daniel Skovronsky and Jacob Van Naarden will also expand their roles to support these initiatives.

LLY

Nov 6, 2025

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Eli Lilly has reached an agreement with the U.S. government to enhance access to its obesity treatments, specifically Zepbound and orforglipron, for Medicare beneficiaries at a reduced cost of $50 per month. This initiative aims to benefit nearly 40 million Americans suffering from obesity, addressing a significant health crisis linked to various diseases. Lilly's commitment to innovation and affordability is underscored by its previous initiatives, including capping insulin costs.

LLY

Nov 6, 2025

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

Eli Lilly announced positive Phase 2 trial results for eloralintide, a selective amylin receptor agonist, showing significant weight loss in adults with obesity. The trial demonstrated weight reductions ranging from 9.5% to 20.1% compared to placebo. Lilly plans to initiate Phase 3 studies by the end of the year, highlighting eloralintide's potential as a new obesity treatment.

LLY

Nov 3, 2025

Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Eli Lilly plans to invest €2.6 billion in a new manufacturing facility in Katwijk, Netherlands, aimed at boosting its production capacity for oral medicines. This facility will create 500 permanent jobs and 1,500 construction jobs, while incorporating advanced technologies to enhance manufacturing efficiency. The expansion is part of Lilly's strategy to strengthen its global supply chain and respond to regional demand.

LLY

Nov 3, 2025

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within...

Eli Lilly and Company announced plans to build a $3 billion manufacturing facility in Katwijk, Netherlands, aimed at boosting oral medicine production. This new site will create 500 permanent jobs and an estimated 1,500 construction jobs, enhancing the company's global supply chain. Notably, it will support the manufacturing of orforglipron, an innovative treatment for obesity. Lilly's investment is contingent on obtaining necessary permits and approvals, with a commitment to sustainable operations and carbon neutrality built into the project.

LLY

Oct 30, 2025

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance

Eli Lilly reported a strong third-quarter for 2025, achieving a 54% increase in revenue driven by demand for its incretin portfolio. The company advanced its orforglipron drug through multiple Phase 3 trials and received FDA approval for Inluriyo, enhancing its pipeline. Lilly also announced plans to expand manufacturing capacity with new facilities in Virginia and Texas, while raising its full-year revenue guidance.

LLY

Oct 29, 2025

Lilly anuncia una inversión de más de 1,200 millones de dólares en su planta de Puerto Rico para aumentar la capacidad de manufactura de medicamentos orales en Estados UnidosUSA - españolUSA - English

Eli Lilly announced a planned investment of over $1.2 billion to expand its manufacturing facility in Puerto Rico. This expansion aims to increase production capacity for oral medications, including orforglipron, an oral GLP-1 receptor agonist. The project is expected to create 1,100 jobs and incorporates advanced manufacturing technologies. The initiative underscores Lilly's commitment to enhancing its manufacturing capabilities in the U.S.

LLY

Oct 29, 2025

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United StatesUSA - EnglishUSA - español

Eli Lilly announced a $1.2 billion investment to enhance its manufacturing site in Puerto Rico. This expansion aims to boost production capacity for oral solid medicines, including orforglipron, and will create numerous jobs. The project is part of Lilly's broader commitment to U.S. manufacturing and is expected to begin construction in 2026.

LLY

Oct 29, 2025

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials...

Eli Lilly and Walmart announced a collaboration to enhance patient access to Zepbound through LillyDirect, allowing users to obtain self-pay single-dose vials at Walmart pharmacies nationwide. This partnership represents a strategic effort to offer convenient and cost-effective options for patients managing obesity. By mid-November, the vials will be available with pricing that provides over 50% discount compared to other obesity medications. This development aims to reduce the burden of managing chronic conditions while expanding the reach of Lilly's innovative healthcare services.

LLY

Oct 28, 2025

Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in...

Eli Lilly and Company has announced the development of the industry's most powerful supercomputer in collaboration with NVIDIA. This AI-driven supercomputer aims to transform drug discovery, making the process faster and more efficient by allowing extensive molecule experimentation. Additionally, Lilly plans to leverage this technology for manufacturing improvements and enhanced medical imaging, contributing to more personalized patient care. However, the endeavor includes risks associated with the implementation and success of AI in drug research.

LLY

Oct 28, 2025

Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact Eli Lilly and Company (NYSE: LLY) today announced its roster of Team USA athletes for the Olympic and Paralympic Winter Games Milano Cortina 2026,...

Eli Lilly and Company (NYSE: LLY) has announced its support for Team USA athletes participating in the 2026 Olympic and Paralympic Winter Games in Milano Cortina. The initiative emphasizes the connection between athletic performance and holistic health, showcasing diverse athletes who advocate for health and well-being. Lilly also extends its Milestones into Meaning™ program, pledging $5,000 donations to U.S. nonprofits for each medal won, aiming to enhance community health care access. This partnership reflects Lilly's commitment to turning athletic achievements into lasting community impact.

LLY

Oct 27, 2025

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly...

Eli Lilly has received FDA approval for a single-injection maintenance regimen of Omvoh (mirikizumab-mrkz) for adults with moderately to severely active ulcerative colitis. This new regimen replaces the previous two-injection approach, providing a more convenient treatment option. The approval follows two earlier approvals this year for Crohn's disease and a citrate-free formulation of Omvoh. Available in early 2026, the single-injection product aims to simplify patient management while maintaining treatment efficacy.

LLY

Oct 27, 2025

Lilly declares fourth-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding...

Eli Lilly and Company has announced a dividend of $1.50 per share for the fourth quarter of 2025, payable on December 10, 2025. Shareholders of record will be eligible for these dividends if they hold shares as of November 14, 2025. The announcement illustrates the company's commitment to returning value to shareholders amidst ongoing business activities.

LLY

Oct 27, 2025

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine a spotlight on moderate-to-severe obstructive sleep...

Eli Lilly has partnered with basketball legend Shaquille O'Neal for a nationwide awareness campaign on moderate-to-severe obstructive sleep apnea (OSA). The campaign, titled 'Don't Sleep on OSA,' seeks to educate the public about the symptoms and health impacts of this underdiagnosed condition. O'Neal will share his experiences with OSA to encourage those suffering from related symptoms to seek medical advice. This initiative targets the estimated 24 million adults affected by OSA in the U.S.

LLY

Oct 27, 2025

Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool...

Eli Lilly’s Omvoh (mirikizumab-mrkz) demonstrated promising results in the Phase 3b LUCENT-URGE study, focusing on bowel urgency for ulcerative colitis patients. By Week 28, a substantial number of participants experienced significant improvements in bowel urgency severity, frequency, and deferred stool times. Safety data remained consistent with previous findings, showing no new safety signals. This study represents a pivotal step in addressing the daily challenges faced by patients suffering from ulcerative colitis.

LLY

Oct 24, 2025

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half...

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising results in long-term studies, with around 80% of patients achieving significant skin improvement using a maintenance dosing schedule of once every eight weeks. This approach could offer a less burdensome alternative to the current monthly regimen for treating moderate-to-severe atopic dermatitis. The company has submitted this data to the FDA for a label update, potentially establishing EBGLYSS as a first-line biologic therapy. The findings will be presented at the upcoming Fall Clinical Dermatology Conference.

LLY

Oct 24, 2025

Lilly to Acquire Adverum Biotechnologies Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene...

Eli Lilly and Company has announced its acquisition of Adverum Biotechnologies, a clinical-stage company focusing on gene therapy for vision loss associated with wet age-related macular degeneration (wAMD). The lead product candidate, Ixo-vec, is a Phase 3 gene therapy aimed at offering a one-time treatment option for this chronic condition. The merger includes a cash offer of $3.56 per share along with potential milestone payments, with the expectation that the transaction will close in Q4 2025. This acquisition is anticipated to enhance Lilly's portfolio in genetic medicine and expand the accessibility of innovative treatments for millions of patients.

LLY

Oct 24, 2025

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often...

Eli Lilly's Phase 3 BRAVE-AA-PEDS trial for baricitinib has shown that 71% of adolescents aged 12 to under 18 with severe alopecia areata achieved successful scalp hair regrowth after one year. This trial, the largest of its kind, aims to provide treatment options for a demographic that has historically been underrepresented in clinical studies. Following the positive results, Lilly plans to seek a label update from global regulators regarding the use of baricitinib in adolescents.

LLY

Oct 17, 2025

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−,...

Eli Lilly announced that Verzenio (abemaciclib) has extended survival in patients with HR+, HER2- high-risk early breast cancer, according to findings from the Phase 3 monarchE trial. The trial revealed that two years of Verzenio plus endocrine therapy reduced mortality risk by 15.8%. Results also highlighted sustained benefits in disease-free survival and reflected positive safety findings, with no new adverse events noted. This study presents Verzenio as a significant advancement in breast cancer treatment, especially for high-risk patients.

LLY

Oct 16, 2025

Lilly confirms date and conference call for third-quarter 2025 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference...

Eli Lilly and Company (NYSE: LLY) has announced that it will release its third-quarter 2025 financial results on October 30, 2025. The company will hold a conference call on the same day to discuss its financial performance in detail with the investment community and media. Investors and the general public can access a live webcast of the call through Lilly's website.

LLY

Oct 15, 2025

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second...

Eli Lilly and Company has reported positive results from two Phase 3 trials, ACHIEVE-2 and ACHIEVE-5, evaluating its oral GLP-1 treatment, orforglipron. In these trials, orforglipron showed significant reductions in A1C levels compared to active comparators, confirming its effectiveness in managing type 2 diabetes. The trials demonstrated that orforglipron not only lowered blood sugar levels effectively but also resulted in weight loss. Safety profiles indicated common mild adverse events, aligning with previous findings. Lilly plans to submit orforglipron for regulatory approval in 2026.

LLY

Oct 13, 2025

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer ...

Lilly announces it will present new clinical data at the 2025 European Society for Medical Oncology Annual Meeting, showcasing findings from the Phase 3 monarchE trial of Verzenio in high-risk early breast cancer. The presentations will also include results from studies on investigational therapies for various cancers, including ovarian and lung cancers. Lilly's ongoing commitment to advancing cancer care is highlighted by the breadth of its oncology pipeline set for late-stage studies.

LLY

Oct 7, 2025

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients...

Eli Lilly's Omvoh (mirikizumab-mrkz) has become the first IL-23p19 antagonist to demonstrate over four years of clinical and endoscopic remission in patients with ulcerative colitis. Recent data from the LUCENT-3 study highlighted that 80% of patients who achieved remission at one year maintained their condition without corticosteroids. Additionally, these outcomes included significant improvements in bowel urgency. While the long-term safety profile appears consistent, some patients reported serious adverse events necessitating treatment discontinuation.

LLY

Sep 26, 2025

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California,...

Eli Lilly and Company has officially opened its newest Lilly Gateway Labs site in San Diego, designed to support early-stage biotechnology companies. This facility spans 82,514 square feet and offers flexible lab spaces for up to 15 biotech firms. By fostering collaboration between startups and Lilly’s scientific resources, the initiative aims to accelerate drug development and innovation. The opening underscores Lilly's commitment to enhancing the local biotechnology ecosystem and contributing to advanced therapies.

LLY

Sep 25, 2025

Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for...

Eli Lilly's Kisunla (donanemab) has received marketing authorization from the European Commission for treatment of early symptomatic Alzheimer's disease. The therapy showed significant efficacy in slowing cognitive and functional decline, especially when started early in affected patients. Kisunla is unique in that it allows for the completion of treatment once amyloid plaques are minimally reduced, potentially reducing the treatment burden. However, patients may be at risk for serious side effects associated with amyloid-related imaging abnormalities.

LLY

Sep 25, 2025

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg...

Eli Lilly's Inluriyo (imlunestrant) has received FDA approval for treating adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. The approval is based on the EMBER-3 trial, which demonstrated that Inluriyo reduced the risk of progression or death by 38% compared to endocrine therapy. With a once-daily oral dosing option, Inluriyo aims to improve patient treatment experiences. However, the product's label includes a warning for potential embryo-fetal toxicity and reports of serious adverse events.

LLY

Sep 23, 2025

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston,...

Eli Lilly and Company has announced plans to build a $6.5 billion facility in Houston, Texas, aimed at manufacturing active pharmaceutical ingredients. This site will focus on small molecule synthetic medicines and is expected to create over 4,600 jobs, enhancing the local economy. The facility will also produce Lilly's oral GLP-1 receptor agonist, orforglipron, targeting obesity treatment. This investment marks Lilly's ongoing commitment to expand its manufacturing capabilities in the U.S., potentially positioning Texas as a leader in health care innovation.

LLY

Sep 17, 2025

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of...

Eli Lilly announced positive results from the SURPASS-PEDS trial, showing Mounjaro (tirzepatide) effectively reduced A1C levels by an average of 2.2% in children and adolescents with type 2 diabetes after 30 weeks. The trial met all key endpoints, including significant improvements in body mass index (BMI) and fasting serum glucose. Mounjaro's safety profile aligned with findings from adult studies, suggesting its potential as an effective treatment option for this underserved pediatric population. The results will be submitted for regulatory review to expand treatment indications for Mounjaro.

LLY

Sep 17, 2025

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial Eli Lilly and Company (NYSE: LLY) today announced positive topline results from ACHIEVE-3, an open-label randomized Phase 3 clinical trial evaluating ...

Eli Lilly announced positive results from the Phase 3 ACHIEVE-3 trial, showing that orforglipron significantly outperformed oral semaglutide in lowering A1C levels and promoting weight loss. Over 1,600 adults with type 2 diabetes participated in the trial, which lasted 52 weeks and compared various doses of both drugs. Orforglipron not only met its primary endpoint but also demonstrated superior performance across key secondary endpoints. While the safety profile was consistent with earlier studies, orforglipron had higher discontinuation rates due to adverse effects when compared to its competitor.

LLY

Sep 16, 2025

Lilly announces plans to build $5 billion manufacturing facility in Virginia Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in...

Eli Lilly and Company plans to build a $5 billion manufacturing facility in Goochland County, Virginia, which will create 2,450 jobs and support advanced pharmaceutical production. This site, expected to open in five years, is part of Lilly's broader commitment to expanding U.S. manufacturing capabilities. The facility will focus on developing active pharmaceutical ingredients for therapies in oncology and autoimmune diseases. Lilly's investment reflects their long-term vision to enhance local economies and innovate in medicine production.

LLY

Sep 16, 2025

Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) today announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of...

Eli Lilly announced positive results from its Phase 3 ATTAIN-1 trial for orforglipron, an oral GLP-1 receptor agonist, which showed significant weight loss and cardiometabolic improvements. Participants taking the drug lost an average of 27.3 lbs over 72 weeks, with notable reductions in waist circumference and improvements in blood sugar levels among those with prediabetes. While the safety profile aligned with other GLP-1 medications, gastrointestinal side effects were the most common adverse events. Lilly is advancing orforglipron towards global regulatory submissions for the treatment of obesity.

LLY

Sep 11, 2025

Lilly to participate in Bernstein's 2nd Annual Healthcare Forum Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, executive...

Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, the executive vice president and chief financial officer, is scheduled to engage in a fireside chat at 8 a.m. Eastern time. A live audio webcast of the event will be accessible on Lilly's investor website, along with a replay available for around 90 days.

LLY

Sep 9, 2025

Lilly launches new Brain Health Matters campaign in partnership with Julianne Moore, empowering the public to prioritize brain health Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations...

Eli Lilly and Company has launched the 'Brain Health Matters' campaign, aimed at encouraging proactive brain health discussions between individuals and their healthcare providers. The campaign partners with actress Julianne Moore to emphasize the importance of early detection of Alzheimer's disease and routine cognitive assessments. As the population ages, Lilly seeks to promote brain health awareness through various media channels, empowering people to include brain health in their overall wellness plans. The initiative is also timed to coincide with World Alzheimer's Month and aims to expand globally in the future.

LLY

Sep 9, 2025

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that...

Eli Lilly and Company has launched Lilly TuneLab, an AI and machine learning platform aimed at enhancing drug discovery for biotechnology firms. This initiative builds on over $1 billion of Lilly's proprietary research data, providing partners access to valuable AI models. The platform is designed to support early-stage drug development by allowing smaller companies to benefit from advanced AI capabilities. Lilly anticipates that this open-access model will accelerate the creation of new medicines for patients.

LLY

Sep 8, 2025

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful...

Eli Lilly and Company announced positive results from the Phase 3 BRUIN CLL-313 trial for Jaypirca (pirtobrutinib), a reversible BTK inhibitor, demonstrating a statistically significant improvement in progression-free survival compared to bendamustine plus rituximab in treatment-naive patients with CLL/SLL. This study represents the third successful Phase 3 trial for pirtobrutinib, supporting potential label expansions. Safety data aligns with previous findings but highlights serious infection risks. Overall survival data is still pending and expected to mature in 2026.

LLY

Sep 4, 2025

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to...

Eli Lilly and Company announced that the FDA has granted Breakthrough Therapy designation to olomorasib, an investigational drug for treating patients with KRAS G12C-mutant advanced non-small cell lung cancer. This designation is based on encouraging results from clinical trials that suggest olomorasib in combination with KEYTRUDA may improve patient outcomes. Updates on its efficacy and safety will be shared at the IASLC 2025 World Conference on Lung Cancer. However, uncertainties regarding the drug's development and approval status remain.

LLY

Aug 27, 2025

Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival...

Eli Lilly announced positive topline results from the Phase 3 monarchE trial, showing that two years of Verzenio plus endocrine therapy significantly improved overall survival in patients with high-risk early breast cancer. The seven-year analysis demonstrated benefits in invasive disease-free and distant relapse-free survival. This positions Verzenio as the standard of care for hormone receptor positive, HER2 negative, node-positive patients. However, concerns remain regarding adverse effects such as high rates of diarrhea and neutropenia.

LLY

Aug 26, 2025

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an...

Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-2 trial for orforglipron, an oral GLP-1 receptor agonist. The trial demonstrated significant weight loss averaging 22.9 lbs and substantial reductions in A1C levels among participants with obesity or overweight and type 2 diabetes. All primary and secondary endpoints were met, leading Lilly to plan for global regulatory submissions this year. While the treatment showed promise, there were reported gastrointestinal adverse events that could impact patient adherence.

LLY

Aug 25, 2025

Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, ...

Eli Lilly and Company (NYSE: LLY) is set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. Key executives, including Jacob Van Naarden and David Hyman, will engage in a fireside chat at 9:15 a.m. Eastern time. A live webcast will be accessible on Lilly's investor website, providing an opportunity for investors and stakeholders to follow the discussion.

LLY

Aug 22, 2025

Lilly to participate in Wells Fargo 20th Annual Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive...

Eli Lilly and Company (NYSE: LLY) will participate in the upcoming Wells Fargo 20th Annual Healthcare Conference scheduled for September 5, 2025. Patrik Jonsson, the executive vice president and president of Lilly International, is set to take part in a discussion during the event. A live audio webcast of the presentation will be made available on Lilly's investor website, along with a replay for 90 days post-event. This participation emphasizes Lilly's active role in the healthcare sector.

LLY

Aug 20, 2025

Anne White to Retire as Executive Vice President and President, Lilly Neuroscience Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from...

Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, is set to retire on December 31, 2025, after 30 years with the company. Her tenure has been marked by significant advancements in medicines for challenging diseases, including the launch of Alzheimer's treatments. Lilly is currently searching for her successor, with White continuing to serve until her official retirement date. Her contributions have been recognized both internally and externally, highlighting her commitment to inclusion and innovation in medicine.

LLY

Aug 7, 2025

Lilly reports second-quarter 2025 financial results and raises guidance Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year...

Eli Lilly and Company reported a strong financial performance for Q2 2025, with revenue increasing by 38% to $15.56 billion, attributed mainly to rising sales of Zepbound and Mounjaro. The company also highlighted positive advancements in its drug pipeline, particularly in oncology and cardiometabolic health. Net income nearly doubled from the previous year to $5.66 billion, and earnings per share rose to $6.29. Additionally, Lilly raised its full-year revenue guidance to a range of $60 billion to $62 billion, reflecting sustained business growth.

LLY

Aug 7, 2025

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable...

Eli Lilly announced positive results from the Phase 3 ATTAIN-1 trial for orforglipron, an oral GLP-1 receptor agonist aimed at treating obesity. The trial involved 3,127 adults and revealed that participants using the highest dose lost an average of 27.3 lbs over 72 weeks, meeting all primary and secondary endpoints. Lilly is preparing to submit the drug for regulatory approval by the end of the year, although common side effects were noted. The trial results highlight orforglipron's potential as a convenient alternative to injectables in obesity management.

LLY

Jul 31, 2025

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Eli Lilly and Company (NYSE: LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes ...

Eli Lilly announced positive topline results for Mounjaro from the SURPASS-CVOT trial, which demonstrated its non-inferiority to Trulicity in terms of major adverse cardiovascular events. The trial revealed additional benefits of Mounjaro, including a 16% reduction in all-cause mortality and improvements in weight and A1C levels. Conducted over four and a half years, this study enrolled over 13,000 participants across 30 countries, reinforcing Mounjaro's safety and efficacy profile. Plans are in place to submit detailed results to regulatory authorities and present findings at future medical conferences.

LLY

Jul 30, 2025

Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that...

Eli Lilly announced encouraging results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study for its Alzheimer's treatment Kisunla (donanemab-azbt). Over a three-year period, participants demonstrated a gradual slowing of cognitive decline, particularly benefiting from early treatment initiation. Although the therapy showed strong clinical benefits, it is associated with potential side effects, including serious ARIA complications. These findings underscore the importance of early intervention in managing Alzheimer's disease.

LLY

Jul 29, 2025

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), ...

Eli Lilly announced positive results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib), a reversible BTK inhibitor, showing non-inferiority in response rate compared to Imbruvica in patients with CLL/SLL. The trial is notable for including treatment-naive patients and the results trend positively for progression-free survival. Further analysis on progression-free survival is planned for the future. Jaypirca's safety profile remains consistent with earlier studies.

LLY

Jul 25, 2025

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a ...

Eli Lilly has successfully completed its acquisition of Verve Therapeutics, a Boston-based company focused on developing genetic medicines for cardiovascular diseases. This acquisition aims to foster innovative treatments that could provide lifelong cardiovascular risk reduction through a single administration. Lilly officials express optimism about the potential transformation of treatment paradigms for millions of patients worldwide. However, they also acknowledge that the acquisition involves certain risks and uncertainties that could affect the expected outcomes.

LLY

Jul 25, 2025

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...

Eli Lilly's donanemab has received a positive opinion from the European Medicines Agency's CHMP for treating early symptomatic Alzheimer's disease. This approval is based on clinical trial data showing that donanemab significantly slowed cognitive and functional decline. However, the treatment carries risks, including the potential for serious side effects such as ARIA. Lilly continues to commit resources to further development and trials for donanemab in Europe.

LLY

Jul 24, 2025

Lilly confirms date and conference call for second-quarter 2025 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference...

Eli Lilly and Company (NYSE: LLY) is set to announce its financial results for the second quarter of 2025 on August 7, 2025. The company will also host a conference call on the same day at 8:30 a.m. Eastern time to discuss the financial performance in detail. Investors and the public can access a live webcast of this call via Lilly's website, with a replay available afterward.

LLY

Jul 24, 2025

Lilly and Verve announce expiration of Verve tender offer Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and ...

Eli Lilly and Verve Therapeutics announced the expiration of a tender offer to purchase all outstanding shares of Verve at $10.50 each, along with contingent value rights. As of the expiration time on July 23, 2025, over 55% of shares were validly tendered. The acquisition is poised to be finalized on July 25, 2025, subject to the terms of the definitive agreement. Both companies are addressing legal and financial advisory support as they move forward.

LLY

Jul 9, 2025

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended ...

Eli Lilly and Company announced that the FDA has approved a label update for Kisunla, their amyloid-targeting therapy for early symptomatic Alzheimer's disease. The new dosing regimen significantly reduces the incidence of amyloid-related imaging abnormalities (ARIA-E) compared to the original schedule while maintaining efficacy. This advancement aims to enhance patient safety and confidence in treatment options. The label update is based on findings from the TRAILBLAZER-ALZ 6 study, which demonstrated the benefits of the updated dosing strategy.

LLY

Jun 23, 2025

Lilly declares third-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding...

Eli Lilly and Company (NYSE: LLY) has announced a dividend of $1.50 per share for the third quarter of 2025, payable on September 10, 2025. Shareholders of record on August 15, 2025, will be eligible for this payment. The announcement reflects Lilly's confidence in its financial health, although it also includes caution about potential risks in pharmaceutical research and development. The company emphasizes the possibility of variance in actual results compared to expectations due to various uncertainties.

LLY

Jun 22, 2025

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety...

Eli Lilly has reported promising results from three Phase 3 clinical trials evaluating its investigational once-weekly insulin efsitora alfa for adults with type 2 diabetes. The trials demonstrated that efsitora achieved non-inferior A1C reductions compared to established daily insulins, with reduced rates of hypoglycemic events. Lilly plans to submit efsitora for regulatory approval globally by the end of this year. The potential simplified dosing regimen may ease the burden of insulin therapy for patients.

LLY

Jun 21, 2025

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron ...

Eli Lilly announced positive Phase 3 results for orforglipron, an oral GLP-1 receptor agonist for type 2 diabetes. The trial demonstrated significant reductions in A1C levels and weight loss without food and water intake restrictions. The safety profile was consistent with established GLP-1 therapies, although gastrointestinal side effects were noted. Further global trials are forthcoming as Lilly aims for regulatory submission by the end of 2023.

LLY

Jun 17, 2025

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...

Eli Lilly and Company has announced a definitive agreement to acquire Verve Therapeutics for approximately $1 billion, aiming to advance innovative one-time gene editing treatments for cardiovascular disease. Verve's lead product, VERVE-102, targets a gene linked to cholesterol levels and has entered Phase 1b trials with Fast Track designation by the FDA. The agreement includes a contingent value right, potentially increasing the total consideration to $1.3 billion, pending specific developmental milestones. The acquisition enhances Lilly's capabilities in genetic medicines and is expected to close in the third quarter of 2025 upon meeting customary conditions.

LLY

Jun 16, 2025

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available...

Eli Lilly and Company announced the availability of the highest doses of Zepbound (tirzepatide) in single-dose vials for $499 per month, accessible through their LillyDirect Self Pay Pharmacy Solutions. This program, launching on July 7, will allow patients struggling with obesity to access all approved doses regardless of insurance. Clinical trials demonstrate that Zepbound can lead to significant weight loss for adults with obesity and weight-related medical issues. However, usage comes with risks such as thyroid cancer and other severe side effects, emphasizing the need for careful medical supervision.

LLY

Jun 2, 2025

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce,...

Eli Lilly and Company (NYSE: LLY) is set to participate in the Goldman Sachs 46th Annual Global Health Care Conference scheduled for June 10, 2025. Lucas Montarce, the company's executive vice president and chief financial officer, will be featured in a fireside chat at 8 a.m. ET. The event aims to provide insights into Lilly's operations and future directions, with a live audio webcast available on the company's investor website.

LLY

Jun 2, 2025

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC)...

Eli Lilly has presented promising Phase 1 clinical data for its investigational FRα targeting antibody-drug conjugate (LY4170156) at the 2025 ASCO Annual Meeting. The ADC showed a preliminary ORR of 55% and a favorable safety profile in women with platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. Lilly plans to advance this therapy into Phase 3 clinical trials based on these initial results, which suggested efficacy across various FRα expression levels. Notably, about 51% of participants had tumors with low FRα expression.

LLY

May 29, 2025

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), ...

Eli Lilly and Company (NYSE: LLY) announced that it will present new studies on several investigational diabetes medications at the upcoming American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Key presentations will include results from Phase 3 trials of orforglipron, insulin efsitora alfa, and tirzepatide, reflecting significant advancements in diabetes treatment options. Additionally, Lilly will host an investor event during the meetings to discuss insights from its cardiometabolic health portfolio.

LLY

May 27, 2025

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ( SiteOne ), a private biotechnology company developing small molecule inhibitors of ...

Eli Lilly and Company has announced a definitive agreement to acquire SiteOne Therapeutics, a clinical-stage biopharmaceutical company focused on non-opioid pain therapies. This acquisition includes STC-004, a Phase 2 ready Nav1.8 inhibitor aimed at treating chronic pain. Lilly's commitment underscores its intent to address the growing demand for effective pain management solutions without the risk of addiction. The deal involves up to $1 billion in cash for SiteOne stakeholders, contingent upon achieving specified milestones.

LLY

May 22, 2025

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor...

Eli Lilly and Company (NYSE: LLY) has announced details about its presentations scheduled for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key presentations will include findings from studies on investigational drugs imlunestrant, olomorasib, LY4170156, and the existing drug Verzenio. These presentations will cover patient-reported outcomes and safety analyses, along with updates on the efficacy of treatments for advanced breast cancer and KRAS G12C-mutant cancers. The event will be held from May 30 to June 3 in Chicago.

LLY

May 21, 2025

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for...

Eli Lilly and Company has received marketing authorization for Kisunla (donanemab) in Australia, marking a significant milestone in Alzheimer's treatment. The therapy is intended for adults with early symptomatic Alzheimer's disease, particularly those who are ApoE ε4 heterozygotes or non-carriers. Kisunla has demonstrated efficacy in slowing cognitive decline and functional impairment, with data from Phase 3 clinical trials showing promising results. However, the treatment is associated with potential side effects, including serious ARIA events that necessitate careful monitoring.

LLY

May 11, 2025

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and...

Eli Lilly announced positive results from the SURMOUNT-5 trial demonstrating that Zepbound (tirzepatide) outperformed Wegovy (semaglutide) in weight loss efficacy among adults with obesity or overweight conditions. Participants receiving Zepbound achieved an average weight loss of 20.2% compared to 13.7% for those on Wegovy over a 72-week period. Key secondary endpoints also favored Zepbound, with greater responses in both weight loss targets and waist circumference reduction. The findings were shared at the European Congress on Obesity and published in The New England Journal of Medicine.

LLY

May 9, 2025

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned ...

Eli Lilly and Purdue University have announced a significant expansion of their collaboration, committing up to $250 million over eight years. The Lilly-Purdue 360 Initiative aims to accelerate pharmaceutical innovation by enhancing the discovery and delivery of medicines, improving supply chain efficiency, and fostering workforce development. This expanded partnership includes the initiation of four new projects and the integration of existing programs, thus extending the agreement to 2032. Purdue will provide facilities for Lilly researchers, facilitating further collaboration between the institutions.

LLY

May 8, 2025

Lilly announces transitions in executive leadership Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive...

Eli Lilly and Company announced key executive leadership transitions aimed at enhancing its growth strategy. Ilya Yuffa will lead the U.S. business, while Patrik Jonsson will focus on international markets. Kenneth Custer has been promoted to oversee Lilly's Cardiometabolic Health division. These changes are expected to drive sustained growth and improve commercialization of upcoming product launches. The company's leadership underscores a commitment to advancing therapeutic capabilities worldwide.

LLY

May 5, 2025

Lilly declares second-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding...

Eli Lilly and Company has announced a dividend of $1.50 per share for the second quarter of 2025. This dividend will be payable on June 10, 2025, to shareholders who are on record as of May 16, 2025. The announcement highlights Lilly's commitment to returning value to its shareholders, although it also includes caution regarding uncertainties in pharmaceutical research and development. The statement underscores the need for investors to be aware of potential risks that could affect expected outcomes.

LLY

May 2, 2025

Lilly to participate in Bank of America Securities 2025 Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly...

Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2025 Healthcare Conference on May 15, 2025. Lucas Montarce, the company's executive vice president and CFO, is scheduled to take part in a fireside chat at 11:40 a.m. Eastern time. A live audio webcast of the session will be accessible via Lilly's investor website, and a replay will be available for approximately 90 days.

LLY

May 1, 2025

Lilly reports first-quarter 2025 financial results and highlights pipeline momentum Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3...

Eli Lilly and Company reported robust financial results for Q1 2025, showcasing a 45% increase in revenue to $12.73 billion, driven largely by strong sales of its products Mounjaro and Zepbound. The company highlighted notable progress in its pipeline, including a positive Phase 3 trial result for its oral incretin orforglipron. Despite some challenges with pricing and rising research and development costs, Lilly plans to expand manufacturing to meet growing global demand for its medicines. The financial guidance for 2025 remains optimistic, reaffirming a revenue outlook between $58 billion and $61 billion.

LLY

Apr 17, 2025

Lilly confirms date and conference call for first-quarter 2025 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call...

Eli Lilly and Company (NYSE: LLY) has confirmed that it will announce its first-quarter 2025 financial results on May 1, 2025. A conference call will follow on the same day to discuss the company’s financial performance with the investment community and media. This will allow for a live webcast accessible on Lilly's website, ensuring stakeholders can stay informed.

LLY

Apr 17, 2025

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron ...

Eli Lilly announced positive Phase 3 results for orforglipron, the first oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss. The trial demonstrated an average A1C decrease of 1.3% to 1.6% and an average weight loss of 16.0 lbs at the highest dosage. The safety profile was consistent with existing injectable GLP-1 therapies, although gastrointestinal side effects were reported. Following this success, Lilly plans further data presentations and anticipates regulatory submissions for both diabetes and weight management applications.

LLY

Mar 30, 2025

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy...

Eli Lilly announced promising Phase 2 results for lepodisiran, an investigational siRNA therapy aimed at reducing lipoprotein(a), a known cardiovascular risk factor. The study demonstrated a significant average reduction of approximately 93.9% in Lp(a) levels among patients treated with the highest dose over a duration of 180 days. Additionally, sustained reductions were observed for nearly 1.5 years in some cases. While the results highlight the potential of lepodisiran as a treatment option, there were some reported adverse events and a death in one of the dose groups.

LLY

Mar 27, 2025

LillyDirect platform expands to facilitate access to Alzheimer's disease care Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth...

Eli Lilly and Company has expanded its LillyDirect digital healthcare platform to enhance access to in-person and telehealth providers for Alzheimer's disease care. This initiative aims to tackle the long wait times for diagnosis, particularly affecting patients in rural and underserved areas. The new resources focus on facilitating timely diagnosis and management of the disease, addressing the urgent needs expressed by both healthcare providers and patients. Lilly's commitment is further emphasized by the inclusion of independent provider connections, which aim to alleviate barriers to care.

LLY

Mar 25, 2025

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be...

Eli Lilly and Company (NYSE: LLY) announced the forthcoming presentation of preclinical data targeting SMARCA2 and KRAS mutations at the 2025 AACR Annual Meeting. The data will be shared in oral presentations, highlighting the effectiveness of their selective inhibitors in preclinical models. Both LY4050784 and LY4066434 are currently advancing in Phase 1 studies, showcasing Lilly's commitment to developing innovative cancer therapies.

LLY

Mar 8, 2025

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe...

Late-breaking results from the Phase 3 BRAVE-AA-PEDS study demonstrated that adolescent patients with severe alopecia areata who received baricitinib showed significant hair regrowth. At Week 36, 42.4% achieved 80% or more scalp hair coverage. Additionally, patients experienced eyebrow and eyelash regrowth compared to those receiving a placebo. The treatment's safety profile was consistent with previous studies, although common adverse events included acne and respiratory infections. Further data from this study will be presented in future meetings.

LLY

Mar 7, 2025

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87%...

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising results for patients with moderate-to-severe atopic dermatitis, with data from a long-term extension study revealing that 50% of patients achieved complete skin clearance over three years. The treatment not only demonstrated a high clearance rate but also significantly improved related symptoms like itch and skin pain. Approved as a monotherapy in 2024, EBGLYSS is hailed by experts as a viable first-line biologic treatment option. These results will be presented at the American Academy of Dermatology Annual Meeting.

LLY

Feb 28, 2025

Lilly to participate in Leerink Partners Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly...

Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, the executive vice president and CFO of Lilly, will engage in a fireside chat at 9:20 a.m. Eastern time. A live audio webcast of the discussion will be available on the company's investor website, along with a replay for approximately 90 days following the event.

LLY

Feb 28, 2025

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...

Eli Lilly announced a positive opinion from the EMA's CHMP for Jaypirca (pirtobrutinib), targeting adults with relapsed or refractory chronic lymphocytic leukemia. This recommendation was based on the results of the BRUIN CLL-321 Phase 3 trial, the first randomized study focused solely on patients who have been previously treated with a BTK inhibitor. The trial demonstrated significant improvements in progression-free survival and time to next treatment. Jaypirca offers a new treatment option for a patient group facing considerable unmet medical needs.

LLY

Feb 26, 2025

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across ...

Eli Lilly and Company announced plans to invest over $50 billion in U.S. manufacturing, significantly boosting its domestic medicine production. The company is set to build four new pharmaceutical manufacturing sites, creating approximately 13,000 high-wage jobs and reshoring key capabilities. This investment reflects Lilly's optimism about its therapeutic pipeline and commitment to enhancing American innovation in the pharmaceutical sector. The expansion aims to meet anticipated demands for safe and reliable medicines while positively impacting local economies.

LLY

Feb 25, 2025

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with...

Eli Lilly & Company has announced the launch of new single-dose vials of Zepbound (tirzepatide) in 7.5 mg and 10 mg doses, priced at $499 each as part of their Self Pay Journey Program. In addition, the prices of their existing 2.5 mg and 5 mg vials have been reduced to make the medication more affordable for self-pay patients. This move is part of Lilly's broader initiative to enhance accessibility to obesity treatment amid growing concerns about healthcare systemic coverage for such treatments. While the changes have been positively received, industry experts emphasize the need for comprehensive coverage solutions for patients with obesity.

LLY

Feb 18, 2025

Lilly to participate in TD Cowen's 45th Annual Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive...

Eli Lilly and Company (NYSE: LLY) is set to participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, the executive vice president and president of Lilly Oncology, will partake in a fireside chat at 1:50 p.m. Eastern time. A live audio webcast will be available on Lilly's investor website, with a replay accessible for approximately 90 days.

LLY

Feb 7, 2025

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with...

Eli Lilly and Company reported promising results from the VIVID-2 study, showing that more than 90% of patients treated with Omvoh (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission over two years. Additionally, nearly 90% maintained endoscopic response during the same period. This underscores Omvoh's position as a leading treatment in its class, with approvals already secured in multiple regions. The long-term safety profile remains consistent with previous findings, although a small percentage of patients did experience adverse events.

LLY

Feb 6, 2025

Lilly reports full Q4 2024 financial results and provides 2025 guidance Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared...

Eli Lilly and Company reported a remarkable 45% increase in revenue to $13.53 billion for Q4 2024, largely fueled by strong sales of Mounjaro and Zepbound. The company's net income more than doubled, growing to $4.41 billion, and earnings per share saw a significant rise. Despite these positive results, Lilly faced challenges with declining sales from Trulicity and lower realized prices affecting the overall revenue. Looking ahead, the company is optimistic about maintaining momentum into 2025 with several promising clinical trials on the horizon.

LLY

Jan 23, 2025

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will...

Eli Lilly and Company will announce its fourth-quarter 2024 financial results and provide guidance for 2025 on February 6, 2025. The company will host a conference call at 10 a.m. Eastern time to discuss its financial performance with investors and media. A live webcast will be accessible via Lilly's website, along with a replay for those unable to attend the live event.

LLY

Jan 15, 2025

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the...

Eli Lilly's Omvoh (mirikizumab-mrkz) has received FDA approval for the treatment of moderately to severely active Crohn's disease in adults, following its prior approval for ulcerative colitis. The decision is based on positive results from the Phase 3 VIVID-1 trial, which showcased significant benefits, including high rates of clinical remission and endoscopic response. With both FDA approvals, Omvoh positions itself as a novel treatment option for patients suffering from inflammatory bowel diseases. Eli Lilly is also pursuing global regulatory approvals to increase access to this therapy.

LLY

Jan 14, 2025

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which...

Eli Lilly and Company has updated its revenue guidance for 2024, forecasting worldwide revenue to reach approximately $45 billion, reflecting a 32% increase year-over-year. Additionally, the company set its 2025 revenue expectations between $58 billion and $61 billion, bolstered by strong performances from several key products. However, the Q4 2024 revenue outlook has been reduced by $400 million compared to previous guidance due to slower-than-anticipated growth and inventory issues. Despite these challenges, the company aims to enhance production capacity significantly in the coming year.

LLY

Jan 13, 2025

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ( Scorpion ), a private biotechnology company developing small molecule precision...

Eli Lilly and Company has announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program, which includes the promising drug STX-478. This acquisition aims to enhance Lilly's oncology pipeline and potentially address treatment needs in hormone-positive breast cancer, with STX-478 currently in Phase 1/2 clinical trials. The unique mechanism of STX-478 selectively targets cancerous cells while sparing healthy ones, promising improved efficacy and tolerability. However, the transaction is subject to customary closing conditions and involves inherent risks in drug development.

LLY

Jan 7, 2025

Lilly to participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and...

Eli Lilly and Company (NYSE: LLY) is set to participate in the 43rd Annual J.P. Morgan Healthcare Conference scheduled from January 13-16, 2025. CEO David A. Ricks will conduct a fireside chat on January 14 at 5:15 p.m. Eastern time. Interested parties can access a live audio webcast through Lilly's investor website, with a replay available for 30 days following the event.

LLY

Dec 20, 2024

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only...

Eli Lilly's Zepbound (tirzepatide) has received FDA approval as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Clinical trials showed that Zepbound significantly reduced breathing interruptions during sleep and helped patients achieve substantial weight loss. After one year of treatment, up to 50% of participants no longer exhibited OSA symptoms. However, the approval comes with warnings about serious side effects, including potential thyroid tumors.

LLY

Dec 17, 2024

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company...

Eli Lilly and EVA Pharma have received regulatory approval for insulin glargine injection in Egypt, marking a significant advancement in diabetes management. This collaboration aims to increase access to affordable insulin for up to one million people living with diabetes in low- and middle-income countries by 2030. The project involves substantial technology transfer and local manufacturing by EVA Pharma, enhancing sustainability in the supply of insulin. Lilly's initiative is part of a broader strategy to improve healthcare access globally, particularly in resource-limited settings.

LLY

Dec 17, 2024

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™...

Eli Lilly and Company announced that its Alzheimer’s treatment Kisunla™ (donanemab-azbt) has been approved by China's National Medical Products Administration (NMPA). This approval marks Kisunla’s entry into the Chinese market, following successful approvals in the US, Japan, and Great Britain. The treatment targets early symptomatic Alzheimer's disease, demonstrating significant results in slowing cognitive decline, especially in patients with mild symptoms. However, caution is warranted due to potential serious side effects, including amyloid-related imaging abnormalities.

LLY

Dec 13, 2024

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the...

Eli Lilly's Omvoh® (mirikizumab) has received a positive opinion from the European CHMP for treating adults with moderately to severely active Crohn's disease. This recommendation is based on results from the Phase 3 VIVID-1 trial, which highlighted significant improvements in clinical outcomes and histologic measures of inflammation. If approved by the European Commission, Omvoh will offer a new treatment option for patients who have previously failed other therapies. The findings were recently published in The Lancet and presented at an annual gastroenterology meeting.

LLY

Dec 11, 2024

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients...

Eli Lilly announced positive results from the Phase 3 EMBER-3 study of imlunestrant in patients with ER+, HER2- advanced breast cancer. As a monotherapy, imlunestrant showed a 38% reduction in risk of progression or death compared to standard therapy. Notably, in combination with Verzenio, it achieved a 43% risk reduction. These findings, which will be presented at the San Antonio Breast Cancer Symposium, signify a potential new oral treatment option for patients previously treated with aromatase inhibitors.

LLY

Dec 9, 2024

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible)...

Eli Lilly announced positive results from the Phase 3 BRUIN CLL-321 trial, which evaluated pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with covalent BTK inhibitors. The trial showed that pirtobrutinib reduced the risk of disease progression or death by 46% compared to the control group and prolonged the median time to next treatment by 23.9 months. This study is significant as it is the first randomized Phase 3 trial conducted solely in BTK inhibitor pre-treated patients, addressing a critical need for new treatment options in this population. The results will be presented at the upcoming ASH Annual Meeting.

LLY

Dec 9, 2024

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5...

Eli Lilly and Company has announced a new $15 billion share repurchase program, following the completion of a previous $5 billion program. Additionally, for the seventh consecutive year, the company will increase its quarterly dividend by 15%, declaring a dividend of $1.50 per share for Q1 2025. The company's executive vice president mentioned a strong growth profile and a commitment to returning capital to shareholders while continuing to invest in research and development. The share repurchase program will be executed over the next three years at management's discretion.

LLY

Dec 9, 2024

CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its...

CORE Kidney has partnered with Boehringer Ingelheim and Eli Lilly to promote kidney health at the 2025 Tournament of Roses Parade. The initiative aims to educate those at risk of kidney disease, particularly individuals with type 2 diabetes and high blood pressure, about the need for comprehensive testing. The float titled "It's In Your Hands: It Takes 2" will visually and musically engage the public on the importance of blood and urine tests for kidney health. The event features Pro Football Hall of Famer Brian Dawkins, emphasizing the necessity of proactive health management among at-risk communities.

LLY

Dec 5, 2024

Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company...

Eli Lilly and Company (NYSE: LLY) has announced a $3 billion expansion of its manufacturing facility in Kenosha County, Wisconsin. This expansion will enhance the production of diabetes, obesity, and future pipeline medicines, while also creating 750 highly skilled jobs. Construction is set to begin next year, contributing to Lilly's ongoing strategy of extensive investment in manufacturing capabilities. The initiative will also integrate advanced automation technologies to improve efficiency in their operations, further solidifying Wisconsin's role in Lilly's global manufacturing network.

LLY

Dec 4, 2024

Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound®...

Eli Lilly announced favorable topline results from the SURMOUNT-5 trial, showing that its weight-loss drug, Zepbound (tirzepatide), significantly outperformed Wegovy (semaglutide) in weight loss effectiveness. After 72 weeks, patients on Zepbound lost an average of 20.2% of their body weight, compared to 13.7% for those on Wegovy. The results indicate that 31.6% of patients on Zepbound experienced a loss of at least 25% body weight. Despite its effectiveness, both treatments reported mild to moderate gastrointestinal side effects, and Zepbound carries significant risks linked to serious adverse effects.

LLY

Nov 19, 2024

Lilly announces changes on board of directors Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024....

Eli Lilly and Company (NYSE: LLY) announced the election of Jon Moeller to its board of directors, effective December 1, 2024, while Karen Walker will resign from her position on December 31, 2024, but will continue to collaborate with the company on digital initiatives. Moeller, currently the CEO of Procter & Gamble, is expected to bring valuable insights from his extensive experience in strategic and operational leadership to Lilly's board. Walker has been a significant contributor since 2018, mentoring leaders and providing insights into talent development and technology strategy.

LLY

Nov 18, 2024

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered...

Eli Lilly announced positive results from the Phase 2 study of muvalaplin, an oral treatment for elevated lipoprotein(a) levels associated with cardiovascular risk. The study found that muvalaplin significantly lowered Lp(a) levels in adults at multiple tested doses, meeting primary and secondary endpoints effectively. These findings represent a potential advancement in cardiovascular disease management, as existing therapies do not address Lp(a) levels. The treatment was generally well tolerated, with no reported deaths.

LLY

Nov 16, 2024

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk...

Eli Lilly and Company has announced promising results from the SUMMIT Phase 3 trial, where tirzepatide demonstrated a significant 38% reduction in the risk of worsening heart failure events in adults suffering from heart failure with preserved ejection fraction (HFpEF) and obesity. The study also showed improvements in exercise capacity and symptoms related to heart failure. With submissions for regulatory approval already initiated, if approved, tirzepatide could become a groundbreaking treatment option for this patient population. The trial met all primary and secondary endpoints, marking a potential new standard of care in managing obesity-related heart failure.

LLY

Nov 13, 2024

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the...

Eli Lilly and Company announced positive results from the Phase 3 SURMOUNT-1 study, which assessed tirzepatide in adults with pre-diabetes and obesity. The study found that participants experienced an average weight loss of 22.9% and demonstrated a 94% reduction in the risk of progressing to type 2 diabetes over a 176-week period. Nearly all participants remained diabetes-free by the study's conclusion, highlighting the potential of tirzepatide as a long-term therapeutic option for weight management and diabetes prevention.

LLY

Nov 5, 2024

Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine...

Eli Lilly and Company (NYSE: LLY) has announced that data from studies of Jaypirca® (pirtobrutinib), a Bruton's tyrosine kinase inhibitor, will be presented at the 2024 American Society of Hematology Annual Meeting. The Phase 3 BRUIN CLL-321 study results will compare Jaypirca against other treatment options in patients previously treated with BTK inhibitors. Additionally, poster presentations will cover real-world data analyses related to chronic lymphocytic leukemia and a novel bispecific antibody for B-cell malignancies.

LLY

Nov 1, 2024

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor...

Eli Lilly recently announced it will present data from its Phase 3 EMBER-3 study of imlunestrant, an oral selective estrogen receptor degrader, at the upcoming San Antonio Breast Cancer Symposium. The EMBER-3 trial evaluates imlunestrant's efficacy in combination with the CDK4/6 inhibitor Verzenio among patients with advanced ER+, HER2- breast cancer who have undergone prior endocrine therapy. Additionally, Lilly will share further findings related to breast cancer treatment and investigational new therapies during the symposium.

LLY

Oct 30, 2024

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from...

Eli Lilly and Company reported its Q3 2024 financial results, showcasing a notable 42% revenue increase when excluding divestiture activities. This growth is primarily attributed to strong performances from new products Mounjaro and Zepbound, contributing to a 20% overall revenue increase compared to Q3 2023. Despite the positive results, international revenue experienced a decline, largely influenced by prior divestitures and inventory adjustments in the U.S. market. The company's focus on oncology, immunology, and neuroscience continues to bolster its growth trajectory, evidencing a solid foundation for future performance.

LLY

Oct 29, 2024

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14%...

Eli Lilly announced positive results from the Phase 3b TRAILBLAZER-ALZ 6 study, which demonstrated a modified dosing regimen of donanemab reduces ARIA-E rates in early symptomatic Alzheimer's patients. The study showed a decrease in ARIA-E from 24% to 14% compared to traditional dosing, while maintaining similar levels of amyloid plaque reduction. Lilly plans to submit these findings to global regulators for a potential label update for its Alzheimer's treatment, Kisunla. The study indicates a promising direction for optimizing therapy in Alzheimer's disease with the modified titration regimen.

LLY

Oct 28, 2024

Lilly declares fourth-quarter 2024 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding...

Eli Lilly and Company has announced a dividend of $1.30 per share for the fourth quarter of 2024, payable on December 10, 2024, to shareholders recorded by November 15, 2024. This move showcases the company's ongoing commitment to providing returns to its investors. Lilly has a rich history of advancing medical science and is actively working on solutions for significant health challenges, including diabetes and cancer. The announcement comes amid the company's focus on enhancing patient accessibility to its medicines.

LLY

Oct 28, 2024

Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease Eli Lilly and Company (NYSE: LLY) announced results from two, multi-year, Phase 3 studies that showed patients treated with mirikizumab sustained...

Eli Lilly and Company announced results from two Phase 3 studies showing that their drug, mirikizumab, sustained long-term remission in patients with inflammatory bowel diseases. Data revealed that more than 80% of patients with moderately to severely active ulcerative colitis maintained remission over three years, while over 50% of Crohn's disease patients did the same for up to five years. Mirikizumab is the first IL23p19 antagonist to report these long-term efficacy results and is FDA-approved for ulcerative colitis. It currently awaits FDA review for Crohn's disease treatment.

LLY

Oct 25, 2024

Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab In first dedicated study of a selective IL-13 inhibitor in patients previously treated with dupilumab, the majority of patients had a history of...

Eli Lilly's EBGLYSS has demonstrated significant efficacy in improving skin clearance and itch relief for patients with moderate-to-severe atopic dermatitis who previously stopped dupilumab treatment. In a Phase 3b study, a majority of subjects showed improvement in challenging areas such as the face and hands. The drug maintained a consistent safety profile, with few adverse events leading to discontinuation. These findings will be presented at the Fall Clinical Dermatology Conference and support EBGLYSS as a viable first-line treatment option.

LLY

Oct 23, 2024

Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing...

Eli Lilly's donanemab, marketed as Kisunla, has received marketing authorization from the Medicines and Healthcare products Regulatory Agency in Great Britain for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults. This approval, the third major market authorization for donanemab after the U.S. and Japan, allows treatment specifically for apolipoprotein E4 heterozygotes and non-carriers. Donanemab has shown significant results in clinical trials, demonstrating efficacy in slowing cognitive decline. However, it is associated with serious side effects, including ARIA, which require careful monitoring.

LLY

Oct 16, 2024

Lilly confirms date and conference call for third-quarter 2024 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call...

Eli Lilly and Company (NYSE: LLY) is set to announce its third-quarter 2024 financial results on October 30, 2024. Along with the results, the company will host a conference call that is slated to start at 10 a.m. Eastern time. This call aims to provide further insights into Lilly's financial performance, facilitating communication with investors and the media. A live webcast of the call will be available on the company's website, with a replay offered thereafter.

LLY

Oct 16, 2024

Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies Results from the national Urgent Conversations survey, announced today by Eli Lilly and Company (NYSE: LLY), found that over half (60%) of the...

Eli Lilly's recent survey reveals that a significant majority of Americans with ulcerative colitis face challenges locating public restrooms during emergencies. The survey, which involved 1,800 participants, indicated that 84% of those with ulcerative colitis struggle to find accessible facilities. In response, the Crohn's & Colitis Foundation launched the 'We Can't Wait' app to help locate public restrooms and improve access. Additionally, Eli Lilly's newly approved treatment Omvoh offers promise for better management of ulcerative colitis symptoms.

LLY

Oct 14, 2024

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with...

Eli Lilly announced positive results from a Phase 3 study showing that mirikizumab achieved better histologic responses in patients with moderately to severely active Crohn's disease compared to ustekinumab. The study, named VIVID-1, is noted for its rigorous analysis aligned with recent European guidelines on mucosal evaluation. The results, which were presented at UEG Week in Vienna, reflect a growing body of evidence supporting mirikizumab as a promising treatment option. Additionally, Lilly has submitted marketing applications for mirikizumab in several regions globally.

LLY

Oct 2, 2024

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced...

Eli Lilly and Company announced a $4.5 billion investment in the Lilly Medicine Foundry, a new facility in Indiana aimed at advancing drug production and development. The center will uniquely combine research and manufacturing to optimize processes and scale production for clinical trials. This investment raises Lilly's total U.S. capital commitment since 2020 to over $23 billion and is expected to create 400 high-skilled jobs. The site, located in the LEAP Research and Innovation District, will also focus on reducing costs and environmental impact.

LLY

Sep 25, 2024

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSS™ treatment at Week 16 in the...

Eli Lilly announced that more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSS treatment at Week 16 maintained sustained skin clearance for up to three years. Nearly 87% of participants did not need high-potency topical corticosteroids or systemic treatments throughout the study duration. The results demonstrate durable efficacy and consistent safety over the long term, reinforcing EBGLYSS as a viable treatment option for patients. The data will be presented at the European Academy of Dermatology and Venereology Congress in Amsterdam.

LLY

Sep 24, 2024

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli ...

Eli Lilly's Kisunla (donanemab-azbt) has been approved in Japan for treating adults with early symptomatic Alzheimer's disease. This is the second major market approval for the drug, following its initial approval in the United States in July 2024. The approval is based on positive results from the TRAILBLAZER-ALZ 2 Phase 3 study, which demonstrated significant cognitive and functional benefits for patients. However, the drug's use comes with potential serious side effects, including amyloid-related imaging abnormalities.

LLY

Sep 13, 2024

FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 ...

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has received FDA approval for treating moderate-to-severe atopic dermatitis in adults and children aged 12 and older. This biologic therapy offers a new first-line option for patients who have not effectively controlled their condition with topical treatments. Clinical studies demonstrated significant improvements in skin clearance and itch relief within weeks of treatment. EBGLYSS will be available soon in the U.S., supported by a patient access program for eligible individuals.

LLY

Sep 12, 2024

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of...

Eli Lilly and Company has announced a major $1.8 billion investment to expand its manufacturing footprint in Ireland, including a $1 billion enhancement of its Limerick site. This expansion aims to increase production of biologic active ingredients for Alzheimer's treatments and other medicines. Additionally, Lilly is investing $800 million in its Kinsale facility for diabetes and obesity treatments. The initiative is expected to create 150 new jobs and is part of Lilly's broader strategy to enhance its global manufacturing capabilities while committing to sustainability.

LLY

Sep 10, 2024

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa...

Eli Lilly and Company announced positive results from the QWINT-2 phase 3 trial for once-weekly insulin efsitora alfa, showing it delivered a significant A1C reduction that is comparable to daily insulin degludec. Efsitora achieved a reduction of 1.34% in A1C levels, and participants benefited from increased time in target glucose range without added hypoglycemia risk. The findings were published in The New England Journal of Medicine and presented at the EASD Annual Meeting 2024, highlighting the potential of efsitora to ease treatment burden for those starting insulin therapy. The results suggest that efsitora could greatly impact the management of type 2 diabetes patients seeking more convenient treatment options.

LLY

Sep 10, 2024

With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa...

Eli Lilly announced positive results from the QWINT-5 phase 3 trial of insulin efsitora alfa, a once-weekly insulin treatment for type 1 diabetes. The trial showed that efsitora achieved a comparable reduction in A1C levels to that of the daily insulin degludec, with similar overall rates of hypoglycemic events. Despite its potential benefits, efsitora was associated with a higher incidence of severe hypoglycemia in the early treatment period. The findings were presented at the EASD Annual Meeting and published in The Lancet.

LLY

Sep 9, 2024

Lilly appoints Lucas Montarce as executive vice president and chief financial officer Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and ...

Eli Lilly and Company has appointed Lucas Montarce as its new executive vice president and chief financial officer, effective immediately. Montarce has held various finance leadership positions since joining Lilly in 2001, most recently serving as president and general manager for the Spain, Portugal, and Greece hub. CEO David Ricks expressed confidence in Montarce's ability to build on Lilly's financial foundation and drive the company's long-term success, especially during a pivotal moment in its history.

LLY

Sep 5, 2024

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once...

Eli Lilly announced positive topline results from the QWINT-1 and QWINT-3 clinical trials, which evaluated once-weekly insulin efsitora alfa in adults with type 2 diabetes. Efsitora showed non-inferior A1C reduction when compared to daily insulins such as glargine and degludec. The trials indicate that efsitora's fixed-dose regimen may simplify insulin management for patients and improve their quality of life. Both studies' positive results suggest promising applications for efsitora in diabetes care.

LLY

Sep 4, 2024

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to baricitinib to ...

Eli Lilly and EVA Pharma have entered a collaboration to expand access to baricitinib for immunological diseases in 49 low- to middle-income countries in Africa. The initiative targets the treatment of an estimated 20,000 individuals by 2030. This effort aligns with Lilly's 30x30 initiative, aiming to provide healthcare access to 30 million people annually. EVA Pharma plans to begin local production of baricitinib by 2026, bolstering its supply chain and addressing essential healthcare needs in the region.

LLY

Aug 27, 2024

Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients...

Eli Lilly has announced the release of Zepbound® (tirzepatide) single-dose vials at a significantly reduced price, offering better access for adults living with obesity. The new vials are available for self-pay patients, priced at over 50% less than comparable medicines. Clinical studies indicate that Zepbound can facilitate an average weight loss of 15% over 72 weeks when combined with lifestyle changes. However, there are warnings regarding serious side effects, including thyroid tumors and potential kidney issues, along with insurance coverage gaps for obesity treatments.

LLY

Aug 22, 2024

Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden,...

Eli Lilly and Company (NYSE: LLY) is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference scheduled for September 5, 2024. Jacob Van Naarden, the executive vice president and president of Lilly Oncology, will engage in a fireside chat during the event. Attendees can access a live audio webcast of the session through Lilly's Investor website, and a replay will be accessible for approximately 90 days following the event.

LLY

Aug 20, 2024

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SURMOUNT-1 three-year study (176-week treatment period)...

Eli Lilly announced promising results from the SURMOUNT-1 study, demonstrating that tirzepatide significantly reduces the risk of type 2 diabetes by 94% in adults with pre-diabetes and obesity. The long-term, 176-week trial also indicated a substantial average weight loss of 22.9% among participants using the 15 mg dose. Despite the positive outcomes, some participants faced weight regain during a follow-up period after treatment cessation, with certain gastrointestinal side effects reported. The findings will be submitted for peer review and presented at ObesityWeek 2024.

LLY

Aug 16, 2024

Lilly announces retirement of Marschall S. Runge from its Board of Directors Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of...

Eli Lilly and Company (NYSE: LLY) has announced the retirement of Marschall S. Runge, M.D., Ph.D. from its Board of Directors effective August 31, 2024. Dr. Runge has been a director since 2013, serving on the Science and Technology and Ethics and Compliance Committees. He is also the CEO of Michigan Medicine and plans to retire from that position in June 2025, although he will continue to engage with the Medical School as a faculty member. Lilly's CEO, David A. Ricks, thanked Dr. Runge for his contributions during his tenure.

LLY

Aug 16, 2024

Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a...

Eli Lilly and Company has successfully completed its acquisition of Morphic Holding, Inc., enhancing its immunology pipeline with Morphic's oral integrin therapies for inflammatory bowel disease. This strategic move is part of Lilly's commitment to delivering innovative treatments in gastroenterology, building on its existing products like Omvoh. The acquisition allows for potential combination treatments that could improve patient outcomes. Despite the optimism, challenges remain regarding the approval timelines of Morphic's products and the effects on Lilly's operations.

LLY

Aug 13, 2024

Lilly opens state-of-the-art research and development center in the Boston Seaport Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in...

Eli Lilly and Company has inaugurated the Lilly Seaport Innovation Center (LSC) in Boston, a 346,000 square foot facility aimed at enhancing its research in genetic medicine. The center will accommodate around 500 researchers and includes the first Lilly Gateway Labs on the East Coast, fostering collaboration with emerging biotech firms. The facility seeks to accelerate the development of innovative therapies targeting various diseases, while also facing inherent uncertainties related to its future success and scientific objectives.

LLY

Aug 8, 2024

Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for...

Eli Lilly and Company reported impressive financial results for Q2 2024, with a 36% increase in revenue driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company also announced the approval of Kisunla for Alzheimer's disease, marking a significant milestone in treatment options. Despite the overall positive results, declines in Trulicity sales and costs related to anticipated litigation payments could pose challenges. Lilly has also indicated an increase in research and development expenses as part of its growth strategy.

LLY

Aug 1, 2024

Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy...

Eli Lilly's tirzepatide has shown promising results in the SUMMIT phase 3 clinical trial, demonstrating a 38% reduction in heart failure outcomes among adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In addition to significant improvements in symptoms and physical limitations, participants experienced a 15.7% weight loss. The trial met all key secondary endpoints, and safety profiles were consistent with previous studies, though some gastrointestinal adverse effects were observed. Lilly plans to submit these results to regulatory agencies for approval.

LLY

Jul 25, 2024

Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call...

Eli Lilly and Company will announce its second-quarter 2024 financial results on August 8, 2024. A conference call will be held on the same day at 10 a.m. Eastern time for investors, media, and the public. The call will provide detailed insights into the company's financial performance, with a live webcast available on Lilly's website. A replay of the call will also be accessible thereafter.

LLY

Jul 8, 2024

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a...

Eli Lilly and Company has announced a definitive agreement to acquire Morphic Holding, Inc. for a purchase price of $57 per share, totaling approximately $3.2 billion. This acquisition aims to bolster Lilly's immunology pipeline with Morphic's lead oral small molecule inhibitor, MORF-057, intended for treating inflammatory bowel disease. The agreement has been approved by both companies' boards and is expected to close in Q3 2024, pending customary closing conditions. Morphic's technology and ongoing development efforts in integrin therapeutics are anticipated to align well with Lilly's strategic goals in gastroenterology.

LLY

Jul 2, 2024

Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants'...

The FDA has approved Lilly's Kisunla (donanemab-azbt) for treating early symptomatic Alzheimer's disease, showing promising results in slowing cognitive decline. In clinical trials, Kisunla reduced cognitive decline by up to 35% and allowed many patients to stop the treatment after achieving minimal amyloid plaque levels. The treatment has a limited-duration regimen and can minimize costs for patients by reducing the number of infusions needed. However, potential side effects include amyloid-related imaging abnormalities and allergic reactions related to infusions.

LLY

Jun 25, 2024

Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel...

Eli Lilly and Company has announced a collaboration with OpenAI to leverage generative AI for the discovery of novel antimicrobials targeting drug-resistant pathogens. This partnership aims to address the critical issue of antimicrobial resistance (AMR), which poses significant health risks worldwide. Diogo Rau from Lilly emphasized the groundbreaking nature of this collaboration in the fight against AMR. However, the announcement includes a cautionary note about the associated risks and uncertainties in the drug development process.

LLY

Jun 24, 2024

Lilly Declares Third-Quarter 2024 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding...

Eli Lilly and Company has announced a dividend of $1.30 per share for the third quarter of 2024, payable on September 10, 2024. Shareholders of record will be those listed by August 15, 2024. The announcement reflects the company's ongoing commitment to rewarding shareholders amid its extensive efforts in addressing critical health challenges globally.

LLY

Jun 21, 2024

Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary...

Eli Lilly's tirzepatide has shown promising results in treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, achieving a remarkable 62.8% reduction in severity and enabling 51.5% of participants to meet criteria for disease resolution. This was observed in two phase 3 clinical studies, supporting a strong case for FDA approval for this new indication. The drug also demonstrated positive impacts on related cardiometabolic health measures. However, gastrointestinal side effects led to some treatment discontinuations, which will need to be managed in clinical settings.

LLY

Jun 8, 2024

Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to...

Eli Lilly and Company disclosed encouraging results from the SYNERGY-NASH trial, a phase 2 study involving 190 participants with metabolic dysfunction-associated steatohepatitis (MASH). The results revealed that a significant percentage of participants treated with tirzepatide achieved MASH resolution and improvement in fibrosis within 52 weeks compared to placebo. Common side effects were mainly mild to moderate gastrointestinal issues. The company plans to engage with regulatory authorities regarding the next steps for tirzepatide in treating MASH.

LLY

Jun 5, 2024

Lilly announces departure of Anat Ashkenazi, chief financial officer Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside...

Eli Lilly and Company has announced the resignation of Anat Ashkenazi as chief financial officer, who is leaving to pursue a career opportunity outside the pharmaceutical industry. Ashkenazi will continue to serve in her role until July 2024 while an internal and external search for her successor takes place. Lilly's chair and CEO, David A. Ricks, praised Ashkenazi for her 23 years of service and noted the significant growth the company experienced during her tenure as CFO. Her departure marks a notable change in the company's financial leadership.

LLY

Jun 4, 2024

Melissa Seymour to join Lilly as executive vice president of Global Quality Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member ...

Eli Lilly and Company (NYSE: LLY) has announced the appointment of Melissa Seymour as executive vice president of Global Quality, effective July 22, 2024. Seymour previously served as chief quality officer at Bristol Myers Squibb and has extensive experience in quality leadership across various pharmaceutical companies. She will succeed Johna Norton, who is retiring after 34 years with the company. Seymour's experience is expected to further Lilly's commitment to high-quality standards amid their expanding global operations and pipeline growth.

LLY

Jun 1, 2024

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients...

Eli Lilly and Company presented updated data on olomorasib, a second-generation KRAS G12C inhibitor, at the 2024 ASCO Annual Meeting. The findings indicate promising monotherapy activity in various KRAS G12C-mutant advanced solid tumors, particularly non-small cell lung cancer (NSCLC), and highlight its tolerability when combined with pembrolizumab. Efficacy results showed a significant objective response rate in patients, even in those previously treated with a KRAS G12C inhibitor. Ongoing studies aim to further explore olomorasib's potential in first-line treatments, addressing an unmet need for effective options in this patient population.

LLY

May 29, 2024

Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF...

Eli Lilly and Company has announced a $6.5 million donation to UNICEF to support health initiatives for children at risk of noncommunicable diseases in India. This new funding contributes to a total commitment exceeding $20 million since 2022 aimed at improving health outcomes. The initiative seeks to strengthen health systems and enhance the capacity of health workers, focusing on prevention and management of diseases like type 1 diabetes and respiratory illnesses. Lilly's efforts align with its broader initiative to improve access to healthcare for millions in resource-limited settings by 2030.

LLY

May 28, 2024

Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson,...

Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference scheduled for June 10, 2024. Patrik Jonsson, an executive vice president and president of Lilly Diabetes and Obesity, will take part in a fireside chat. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days post-event.

LLY

May 24, 2024

Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new ...

Eli Lilly has announced an expansion of its Lebanon, Indiana facility, committing an additional $5.3 billion, bringing total investment to $9 billion. This marks the largest investment in synthetic medicine active pharmaceutical ingredient manufacturing in the U.S. history. The expansion is designed to enhance production capacity for its diabetes medications, Zepbound and Mounjaro, while also creating 200 new high-skilled jobs. The initiative is supported by state infrastructure improvements and aligns with Lilly's long-term strategy to boost manufacturing and economic growth within Indiana.

LLY

May 23, 2024

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a...

Eli Lilly and Company (NYSE: LLY) announced that it will present data on its oncology pipeline, including studies on Verzenio, Retevmo, olomorasib, and imlunestrant at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include late-breaking data for Verzenio and updates on pediatric trials of Retevmo. The presentations are aimed at showcasing new insights into treatment strategies for advanced cancers. An investor event will accompany these presentations to discuss Lilly's ongoing oncology efforts.

LLY

May 21, 2024

More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without...

In the Phase 3 VIVID-1 study, Eli Lilly's mirikizumab demonstrated significant efficacy in treating Crohn's disease, with over half of patients achieving clinical remission within a year. The study included both naïve patients and those with prior biologic failure, with mirikizumab showing improved outcomes compared to placebo and ustekinumab for several clinical endpoints. Despite a favorable safety profile, the study noted that some patients still experienced adverse events and inadequate treatment responses. Lilly plans to pursue further regulatory submissions for mirikizumab in Crohn's disease.

LLY

May 16, 2024

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating...

Eli Lilly & Company announced positive topline results from phase 3 trials, QWINT-2 and QWINT-4, for once-weekly insulin efsitora alfa in type 2 diabetes. Efsitora demonstrated non-inferior A1C reduction compared to the daily insulins insulin degludec and insulin glargine, showing its potential as a safer and more convenient treatment option. Participants on efsitora achieved significant blood sugar control with fewer treatment burdens and improved adherence possibilities. Further detailed results will be presented at the EASD Annual Meeting 2024.

LLY

May 15, 2024

Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and...

Eli Lilly and Company announced the retirement of Alonzo Weems, the executive vice president of enterprise risk management and chief ethics and compliance officer, effective December 31, 2024. Weems has served the company for 27 years and has played a vital role in the organization's strategic guidance and ethical standards. His leadership helped Lilly achieve significant business performance while emphasizing the importance of integrity. The company will seek a successor to fill his role during his remaining time with the company.

LLY

May 6, 2024

Lilly Declares Second-Quarter 2024 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding...

Eli Lilly and Company (NYSE: LLY) announced a dividend of $1.30 per share for the second quarter of 2024, payable on June 10, 2024, to shareholders of record by May 16, 2024. The company's ongoing commitment to healthcare advancements continues, with a focus on addressing significant health challenges such as diabetes and Alzheimer's disease. Additionally, Lilly emphasizes the importance of diversity in clinical trials and aims to ensure the accessibility of its medications.

LLY

Apr 30, 2024

Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3...

Eli Lilly and Company (LLY) has announced strong financial results for Q1 2024, reflecting a 26% increase in revenue to $8.77 billion. This growth was driven by robust sales of Mounjaro and Zepbound, alongside a notable rise in earnings per share. Despite these successes, Lilly is facing challenges with declining sales of Trulicity and capacity issues due to high demand for its incretin medicines. The company remains optimistic, having raised its full-year revenue guidance by $2 billion.

LLY

Apr 17, 2024

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...

Eli Lilly announced positive topline results from the SURMOUNT-OSA phase 3 trials, demonstrating that tirzepatide significantly reduced the apnea-hypopnea index in adults with obstructive sleep apnea and obesity. The trials achieved all primary and key secondary endpoints, showcasing marked improvements in sleep apnea symptoms and a noteworthy reduction in body weight among participants. Based on these findings, Lilly plans regulatory submissions for approval. However, some adverse events were reported, including gastrointestinal issues and thyroid-related risks.

LLY

Apr 16, 2024

Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call ...

Eli Lilly and Company (NYSE: LLY) is set to announce its first-quarter 2024 financial results on April 30, 2024. The announcement will be accompanied by a conference call at 10 a.m. Eastern time, aimed at providing further details to the investment community and media. Investors and the general public will be able to access a live webcast of the conference call via Lilly's website, and a replay will be available after the event.

LLY

Mar 10, 2024

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of...

Eli Lilly announced promising results from a Phase 3 study of lebrikizumab, an investigational treatment for moderate-to-severe atopic dermatitis, specifically targeting patients with skin of color. The study showed significant improvements in skin clearance and itch relief among participants, addressing the historical lack of representation in clinical trials for this group. No new safety concerns were identified, and Lilly plans to continue research aimed at enhancing care for these patients. Further results from the trial will be shared at upcoming congresses, emphasizing Lilly's commitment to health equity in dermatology.

LLY

Mar 8, 2024

U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and ...

Eli Lilly announced that the FDA will convene an Advisory Committee Meeting to discuss the TRAILBLAZER-ALZ 2 trial of donanemab, aimed at treating early symptomatic Alzheimer's disease. This meeting will focus on the safety and efficacy results, especially considering the unique trial design. While this review stage is unusual and might delay FDA action, Lilly's executives express confidence in donanemab's potential benefits. However, serious risks associated with the treatment, such as amyloid-related imaging abnormalities, remain a concern.

LLY

Mar 7, 2024

Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier...

Eli Lilly and Company has launched the next phase of its 'Get Better' campaign, focusing on obesity treatment. Two films, 'Shame' and 'Big Night', highlight obesity as a serious disease and the responsible use of anti-obesity medications. The campaign aims to improve public understanding and discussion about obesity. However, Lilly acknowledges the potential risks in achieving the campaign's objectives, particularly regarding misconceptions about medication use.

LLY

Mar 5, 2024

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented ...

Eli Lilly and Company (NYSE: LLY) announced that it will present preclinical data related to several agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) at the AACR Annual Meeting in April. The company will showcase three significant presentations, including an anti-Nectin-4 antibody, a KRAS G12D inhibitor, and a selective BRM inhibitor in collaboration with Foghorn Therapeutics. Lilly plans to file IND applications for these programs in 2024, though the company notes inherent risks and uncertainties in drug development.

LLY

Feb 20, 2024

Lilly to Participate in Cowen's 44th Annual Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice...

Eli Lilly and Company (NYSE: LLY) has announced its participation in Cowen's 44th Annual Health Care Conference, scheduled for March 6, 2024. Anat Ashkenazi, the executive vice president and chief financial officer, will join a fireside chat at 9:10 a.m. ET. The event will be available for live listening via an audio webcast on Lilly's Investor website, ensuring that investors and stakeholders can access the information. A replay of the discussion will be accessible for 90 days following the event.

LLY

Feb 9, 2024

Philip Johnson to Retire as Lilly Treasurer Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from...

Eli Lilly and Company has announced the retirement of Philip Johnson, its treasurer, after more than 28 years with the company. Johnson has significantly influenced Lilly's financial operations and talent development. His contributions included leading investor relations and initiatives for underrepresented groups. A successor will be named in the future, but the company acknowledges potential risks associated with this leadership transition.

LLY

Feb 6, 2024

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth...

Eli Lilly and Company reported strong financial results for Q4 2023, with revenues reaching $9.35 billion, a 28% increase year-over-year. Key drivers included significant contributions from new products, particularly Mounjaro and Zepbound. Gross margins also improved, reflecting strong pricing strategies despite some decreases in revenue from established products like Trulicity. The company highlighted its focus on enhancing its pipeline and addressing healthcare challenges as it looks forward to 2024.

LLY

Jan 25, 2024

Johna Norton to Retire as Lilly Executive Vice President of Global Quality Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of...

Eli Lilly announced the retirement of Johna Norton, Executive Vice President of Global Quality, effective July 31, 2024, after 34 years of service. Throughout her tenure, she has played a crucial role in enhancing quality standards and overseeing expansions at Lilly's manufacturing sites. An internal and external search for her successor is currently underway. Norton's contributions have made a significant impacts on the company and its patients, and she has been recognized in the industry for her leadership.

LLY

Jan 23, 2024

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2...

Akouos, Inc., a subsidiary of Eli Lilly, announced promising initial results from its Phase 1/2 clinical trial of AK-OTOF, a gene therapy for OTOF-mediated hearing loss. The trial demonstrated significant hearing restoration within 30 days of treatment in the first participant, marking a potential breakthrough for patients suffering from this genetic condition. The study will present detailed findings at the upcoming ARO MidWinter Meeting. While optimism surrounds the results, the company acknowledges inherent risks and uncertainties in the drug development process.

LLY

Jan 23, 2024

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. Lilly will...

Eli Lilly and Company (NYSE: LLY) announced that it will disclose its fourth-quarter 2023 financial results and provide 2024 financial guidance on February 6, 2024. The company will hold a conference call at 10 a.m. Eastern time to discuss these matters with investors and the media. A live webcast will be available for access, along with a replay on their website following the call.

LLY

Jan 4, 2024

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ Eli Lilly and Company (NYSE: LLY) today announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity,...

Eli Lilly and Company has launched LillyDirect, a comprehensive digital healthcare experience tailored for patients in the U.S. with obesity, migraine, and diabetes. This initiative provides resources such as access to healthcare providers and home delivery of select medications, aimed at easing the patient management process for chronic diseases. LillyDirect is expected to evolve with updates and additional services to enhance patient adherence and healthcare access.

LLY

Jan 2, 2024

Lilly to Participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024. David A. Ricks, Lilly's chair and...

Eli Lilly and Company is scheduled to attend the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024. David A. Ricks, Lilly's chair and CEO, will engage in a fireside chat on January 9 at 5:15 p.m. Eastern time. Investors and media will be able to access a live audio webcast of the discussion on Lilly's Investor website, with a replay available for approximately 30 days thereafter.

LLY

Dec 27, 2023

Lilly Completes Acquisition of POINT Biopharma Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a...

Eli Lilly announced the successful acquisition of POINT Biopharma, specializing in radiopharmaceutical therapies for cancer. The acquisition was completed following a tender offer that saw 67.97% of POINT's shares tendered. Lilly's management expressed optimism about developing innovative therapies through this addition, though the press release also highlighted potential risks associated with the acquisition and drug development processes. The deal signifies Lilly's strategic move into next-generation cancer treatment options.

LLY

Dec 18, 2023

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...

Eli Lilly and Company has announced the extension of its tender offer to acquire POINT Biopharma Global Inc. until December 22, 2023. This decision comes after obtaining all necessary regulatory approvals. So far, around 22.81% of POINT's shares have been validly tendered up to the previous expiration date. However, the company also acknowledges inherent risks related to completing the acquisition and potential competing proposals.

LLY

Dec 11, 2023

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent ...

Eli Lilly and Company announced encouraging updated clinical data from the Phase 1/2 BRUIN trial of their non-covalent BTK inhibitor pirtobrutinib. Presented at the 2023 ASH Annual Meeting, the data reflects efficacy and tolerability in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Notably, pirtobrutinib showed an overall response rate of 81.6% in CLL/SLL patients, while combination treatment with venetoclax achieved a remarkable 96% response rate. The trial's ongoing investigation will further explore the longevity of response and potential for broad clinical utility.

LLY

Dec 11, 2023

Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to...

Lilly's Zepbound™ (tirzepatide) demonstrated significant efficacy in the SURMOUNT-4 study, achieving a total mean weight loss of 26.0% over 88 weeks. The study enrolled adults with obesity or overweight and showed that participants on Zepbound maintained their weight loss compared to those on placebo, who experienced a mean weight regain. The results were published in JAMA, confirming Zepbound's superiority in weight management. Despite the positive outcomes, there were concerns regarding gastrointestinal adverse events, which were the most frequently reported issues during the study.

LLY

Dec 8, 2023

Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the...

Eli Lilly and Company has announced a 15% increase in its quarterly dividend, now set at $1.30 per share, payable on March 8, 2024. This decision reflects the company's strong financial health and commitment to returning value to shareholders. The dividend is declared for shareholders of record as of February 15, 2024. Lilly remains focused on advancing healthcare innovations and addressing significant health challenges globally.

LLY

Dec 5, 2023

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer...

Eli Lilly announced a late-breaking presentation of results from the MONARCH 3 clinical trial at the 2023 San Antonio Breast Cancer Symposium. The trial demonstrated a numerical improvement in overall survival of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor. However, these outcomes did not reach statistical significance. Additional analyses regarding Verzenio's use, along with imlunestrant, are also set to be presented, contributing to the ongoing dialogue about treatment efficacy in this patient population.

LLY

Dec 5, 2023

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults with...

Eli Lilly has announced the availability of Zepbound™ (tirzepatide) injection for adults struggling with obesity or overweight. Approved by the FDA, Zepbound can be accessed through pharmacies in several dosage options following its inclusion in national formularies. The company emphasizes the need for collaboration to improve access for individuals in need. Safety warnings include potential severe side effects such as thyroid tumors and pancreatitis, underscoring the importance of physician oversight during treatment.

LLY

Dec 4, 2023

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...

Eli Lilly and Company has extended its tender offer to acquire POINT Biopharma Global Inc. until December 15, 2023. This extension allows both companies to satisfy the necessary minimum tender condition, with approximately 24.75% of POINT's shares already tendered as of December 1, 2023. All required regulatory approvals for the acquisition have been obtained. However, there are uncertainties regarding shareholder participation and potential competing offers that may impact the acquisition process.

LLY

Dec 1, 2023

Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca® (pirtobrutinib, 100 mg & 50 mg...

Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two lines of prior therapy. This approval is based on results from the BRUIN Phase 1/2 trial, where 72% of participants showed an overall response rate. Jaypirca is noted for being the first non-covalent BTK inhibitor, indicating a novel approach in therapeutic strategies for patients with prior treatment failures. However, the continued approval of Jaypirca relies on further verification of its clinical benefits in ongoing studies.

LLY

Nov 28, 2023

Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of...

Eli Lilly and Company has announced plans to open its first Lilly Gateway Labs location in San Diego in the first half of 2024. This new facility will provide state-of-the-art lab space and unique access to Lilly scientists, fostering collaboration and innovation among early-stage biotech companies. Located in the University Town Center, the site will offer flexible lab space for ten companies and is part of Lilly's broader strategy to support external scientific innovation. This expansion reflects Lilly's commitment to enhancing the life sciences ecosystem in San Diego.

LLY

Nov 17, 2023

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany Eli Lilly and Company (NYSE: LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate,...

Eli Lilly and Company has announced plans to construct a new $2.5 billion high-tech manufacturing facility in Alzey, Germany, aimed at expanding its injectable product manufacturing. This investment will create up to 1,000 skilled jobs and is part of Lilly's strategy to bolster its production capabilities to meet growing demand for its medicines. Alongside the new site, Lilly also plans to invest up to $100 million in the German life sciences ecosystem to foster innovation and strengthen relationships with local partners. The facility is projected to commence operations in 2027, contingent on government approvals.

LLY

Nov 17, 2023

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...

Eli Lilly and Company has extended its tender offer to acquire POINT Biopharma Global Inc. until December 1, 2023, allowing more time to meet the minimum tender condition. The tender offer price is set at $12.50 per share in cash. As of the previous deadline, about 26.45% of POINT's outstanding shares have been validly tendered. While necessary regulatory approvals are in place, uncertainties still surround the completion of the acquisition.

LLY

Nov 14, 2023

Lilly to Participate in Evercore ISI HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D.,...

Eli Lilly and Company (NYSE: LLY) will attend the upcoming Evercore ISI HealthCONx Conference on November 28, 2023. The event will feature a participation from Daniel Skovronsky, M.D., Ph.D., the company's chief scientific and medical officer. A live audio webcast of the session will be available on Lilly's Investor website, with a replay accessible for 90 days following the event.

LLY

Nov 14, 2023

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ( NRC ) has issued its consent for the indirect...

Eli Lilly and Company announced that it has received consent from the U.S. Nuclear Regulatory Commission for the indirect transfer of control of POINT Biopharma's radioactive materials license. This approval is the final regulatory step necessary for Lilly's tender offer to acquire all outstanding shares of POINT Biopharma at a price of $12.50 per share. The tender offer is set to expire on November 16, 2023. Although the acquisition is progressing, Lilly acknowledges inherent risks and uncertainties involved in completing the deal.

LLY

Nov 8, 2023

Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...

Eli Lilly and Company has announced an extension of its tender offer to acquire POINT Biopharma Global Inc. The offer, initially set to expire on November 9, 2023, will now continue until November 16, 2023, to meet outstanding closing conditions. As of November 8, about 14.16% of POINT's outstanding shares have been tendered. The acquisition is anticipated to close near the end of 2023, depending on satisfying various conditions and receiving a majority of outstanding shares.

LLY

Nov 8, 2023

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only...

Eli Lilly's Zepbound™ (tirzepatide) has received FDA approval for chronic weight management in adults with obesity or overweight with related medical problems. This treatment activates both GIP and GLP-1 hormone receptors, offering a novel mechanism for weight loss. Clinical trials indicated an average weight loss of 48 lb at the highest dosage, with a notable percentage of patients achieving significant weight loss. However, Zepbound is associated with risks including gastrointestinal side effects and has specific contraindications that must be considered prior to use.

LLY

Nov 2, 2023

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) ...

Eli Lilly and Company has announced the upcoming presentations of pirtobrutinib at the 2023 ASH Annual Meeting, to be held from December 9-12 in San Diego. The presentations will cover a range of safety and efficacy data from the Phase 1/2 BRUIN study, with a focus on various B-cell malignancies. Specific topics include treatment outcomes for patients with high-risk mantle cell lymphoma and chronic lymphocytic leukemia. Research will also explore resistance mechanisms in treated patients, emphasizing the drug's role as a reversible Bruton's tyrosine kinase inhibitor.

LLY

Nov 2, 2023

Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the...

Eli Lilly and Company reported its financial results for the third quarter of 2023, posting a revenue increase of 37% to $9.5 billion, driven largely by strong sales of Mounjaro and Verzenio. Despite the overall revenue growth, the company experienced a substantial net loss of $57.4 million, compared to a profit of $1.45 billion in the same quarter last year. Lilly's focus on business development saw multiple acquisitions, aiming to expand its product pipeline amidst mixed financial outcomes.

LLY

Nov 1, 2023

Hip-Hop Classic It Takes Two Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is...

Eli Lilly and Boehringer Ingelheim have launched a health initiative named 'It Takes 2' to raise awareness about chronic kidney disease (CKD) among adults, particularly those at risk due to type 2 diabetes and high blood pressure. The initiative features a remix of the classic hip-hop song 'It Takes Two' by Rob Base to emphasize the importance of complete testing for CKD. With tailored resources for healthcare professionals and at-risk individuals, the initiative encourages the use of both eGFR and UACR tests for early diagnosis. The partnership aims to improve awareness and testing compliance to reduce the long-term impacts of CKD.

LLY

Nov 1, 2023

Lilly Declares Fourth-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding...

Eli Lilly and Company (NYSE: LLY) announced a dividend of $1.13 per share for the fourth quarter of 2023, payable on December 8, 2023, to shareholders of record by November 15, 2023. The announcement highlights Lilly's ongoing commitment to enhancing shareholder value while reflecting on its long history of medical innovations that serve millions worldwide. Lilly emphasizes its continuous advancements in various health challenges, including diabetes care and cancer treatment, while acknowledging the inherent uncertainties associated with its business strategies.

LLY

Oct 26, 2023

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion...

Eli Lilly's Omvoh (mirikizumab-mrkz) has received FDA approval as the first interleukin-23p19 antagonist for adults with moderately to severely active ulcerative colitis. Significant efficacy was demonstrated in pivotal trials, with many patients achieving clinical remission over one year of treatment. The approval marks an advancement in treatment options for those who have struggled with other therapies. While there are identified risks associated with the drug, such as potential hypersensitivity reactions and infections, the positive results offer new hope for patients seeking effective treatment alternatives.

LLY

Oct 26, 2023

Lilly to Participate in UBS Biopharma Conference 2023 Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president,...

Eli Lilly and Company (NYSE: LLY) is scheduled to participate in the UBS Biopharma Conference on November 8, 2023. Patrik Jonsson, the executive vice president, will lead a fireside chat during the event. Investors can access a live audio webcast of the chat, along with a replay available for approximately 90 days on Lilly's Investor website. The event underscores Lilly's commitment to open communication with stakeholders.

LLY

Oct 21, 2023

Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023 Eli Lilly and Company (NYSE: LLY) today announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® (selpercatinib) versus...

Eli Lilly announced significant results from the LIBRETTO-431 and LIBRETTO-531 Phase 3 studies of Retevmo (selpercatinib), demonstrating improved progression-free survival in patients with RET fusion-positive non-small cell lung cancer and RET-mutant medullary thyroid cancer. The findings were presented at the ESMO Congress 2023 and published in the New England Journal of Medicine. Notably, Retevmo showed a median PFS of 24.8 months versus 11.2 months with standard therapy in NSCLC patients and provided a 72% improvement in PFS for MTC patients. Despite its promising efficacy, the safety profile indicates potential risks that clinicians must consider.

LLY

Oct 20, 2023

Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a...

Eli Lilly and Company (NYSE: LLY) is set to announce its third-quarter 2023 financial results on November 2, 2023. The company will conduct a conference call at 9 a.m. Eastern time to discuss its financial performance in detail. Investors and the media will have access to a live webcast, with a replay available afterward on Lilly's website.

LLY

Oct 20, 2023

Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years...

Eli Lilly and Company announced positive five-year outcomes from the Phase 3 monarchE study, demonstrating that Verzenio (abemaciclib) combined with endocrine therapy significantly lowers the risk of cancer recurrence in patients with high-risk early breast cancer. The data, presented at the 2023 ESMO Congress, showed a 32% reduction in the risk of invasive disease and a 7.6% increase in invasive disease-free survival. The study reinforces Verzenio's role as the standard of care for this patient population, highlighting sustained benefits beyond the two-year treatment period.

LLY

Oct 20, 2023

Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced...

Eli Lilly's investigational drug, lebrikizumab, has shown promising two-year results in treating patients with moderate-to-severe atopic dermatitis. The ADjoin long-term extension study demonstrated that a significant proportion of patients maintained clear or almost clear skin, relieving itch and reducing disease severity with monthly dosing. The safety profile of lebrikizumab was consistent with previous studies, with common mild to moderate side effects reported. These findings reinforce the drug's potential as a first-line therapy for atopic dermatitis, with further presentations planned at the Fall Clinical Dermatology Conference.

LLY

Oct 15, 2023

Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or...

Eli Lilly's phase 3 SURMOUNT-3 trial results reveal that tirzepatide significantly aids weight loss in adults with obesity or overweight with weight-related comorbidities. After 84 weeks, participants on tirzepatide achieved a mean weight loss of 26.6%, compared to just 3.8% for those on placebo. The trial demonstrated both the efficacy and safety of tirzepatide, which is currently under review by the FDA and EMA for treating obesity. While effective, mild to moderate gastrointestinal side effects were noted in participants taking the drug.

LLY

Oct 12, 2023

Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major ...

Eli Lilly announced that mirikizumab, an investigational treatment for Crohn's disease, successfully met all primary and secondary endpoints in its Phase 3 VIVID-1 trial. The treatment demonstrated significant efficacy, with over half of the patients achieving clinical remission at Week 52 compared to placebo. Lilly plans to submit marketing applications for mirikizumab to the FDA and other regulatory agencies globally in 2024. While the drug showed promise, some adverse events were reported, and it did not surpass ustekinumab in endoscopic response.

LLY

Oct 6, 2023

Lilly Announces Details of Presentations at ESMO Congress 2023 Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a...

Eli Lilly announced the presentation of clinical data at the upcoming ESMO Congress 2023, focusing on three key treatments: Verzenio for breast cancer, Retevmo for certain lung and thyroid cancers, and the investigational drug imlunestrant for breast cancer. Notably, the results from the Phase 3 monarchE study for Verzenio will include a five-year analysis, while Retevmo studies will present interim analyses comparing its efficacy against other therapies. These findings aim to shed light on treatment strategies and outcomes for patients with specific cancer types.

LLY

Oct 4, 2023

Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple...

Loxo@Lilly, a subsidiary of Eli Lilly and Company, announced the presentation of preclinical data for three new oncology programs at the upcoming AACR-NCI-EORTC conference. These include a potent inhibitor targeting KRAS G12D, a pan-KRAS inhibitor, and an anti-Nectin-4 antibody drug conjugate. All three candidates are set to enter clinical trials in 2024, highlighting significant advancements in cancer treatment. Jacob Van Naarden, the president of Loxo@Lilly, emphasized the importance of these developments in addressing unmet medical needs in oncology.

LLY

Oct 4, 2023

Lilly Announces Leadership Transitions Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Mike Mason, executive vice president and president of...

Eli Lilly and Company has announced significant changes to its executive leadership team, including the retirement of Mike Mason and the appointment of Patrik Jonsson as the new president of Lilly Diabetes and Obesity. Daniel Skovronsky will take on additional responsibilities as president of Lilly Immunology. CEO David A. Ricks expressed confidence in the new leadership's ability to drive future growth and innovation in the company's product portfolio. Additionally, Leigh Ann Pusey will leave the company, leading to reassignment of her responsibilities among executives.

LLY

Oct 3, 2023

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a ...

Eli Lilly and Company has announced its acquisition of POINT Biopharma Global, aimed at expanding its oncology capabilities in radioligand therapies for cancer treatment. The acquisition will involve a cash payment of $12.50 per share, valuing POINT at approximately $1.4 billion and bringing advanced therapeutic prospects for conditions such as metastatic castration-resistant prostate cancer. The merger is expected to close by the end of 2023, pending regulatory approvals and shareholder participation. CEO Jacob Van Naarden expressed optimism about integrating POINT's assets with Lilly's resources to develop new, effective cancer treatments.

LLY

Oct 2, 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the...

Eli Lilly and Company announced that the FDA issued a complete response letter for the biologic license application of lebrikizumab, intended for the treatment of moderate-to-severe atopic dermatitis. While the letter raised no issues regarding clinical data or patient safety, it cited findings from an inspection of a third-party manufacturer. Lilly remains confident in the potential of lebrikizumab and plans to collaborate with both the FDA and the manufacturer to resolve the identified issues. The approval timeline for the drug may be impacted by these findings.

LLY

Sep 22, 2023

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in...

Jardiance® (empagliflozin) has been approved by the U.S. FDA for adults with chronic kidney disease (CKD) at risk of progression. The approval is based on findings from the EMPA-KIDNEY trial, which showed a 28% relative reduction in the risk of kidney disease progression and cardiovascular death. Jardiance is specifically not recommended for patients with type 1 diabetes or those with an eGFR below 30 mL/min/1.73 m²., emphasizing its targeted use. This approval marks the fourth for Jardiance stemming from the EMPOWER program, enhancing treatment options for CKD patients.

LLY

Aug 29, 2023

Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12, 2023. Daniel Skovronsky,...

Eli Lilly and Company (NYSE: LLY) will be participating in the Morgan Stanley 21st Annual Global Healthcare Conference, set to take place on September 11-12, 2023. Daniel Skovronsky, the company's chief scientific and medical officer, is scheduled to take part in a fireside chat on September 11. Investors and interested parties will have access to a live audio webcast of the event, with a replay available for 90 days afterward.

LLY

Aug 22, 2023

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the...

Eli Lilly and Company announced topline results from the LIBRETTO-531 study, which evaluated Retevmo against multikinase inhibitors as a treatment for RET-mutant medullary thyroid cancer. The study achieved its primary endpoint of improved progression-free survival, highlighting Retevmo as a preferred initial treatment option. While the results are promising, associated adverse events were consistent with previous findings, including hepatotoxicity and interstitial lung disease. Full trial results will be shared with the medical community in future presentations.

LLY

Aug 14, 2023

Lilly Completes Acquisition of Versanis Bio Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's...

Eli Lilly and Company has successfully completed its acquisition of Versanis Bio, which strengthens Lilly's portfolio by including bimagrumab, currently in a Phase 2b study for obesity treatments. The acquisition is anticipated to yield significant advancements in cardiometabolic disease therapies, as noted by Lilly executives. Notably, the deal involves potential payments totaling up to $1.925 billion based on development milestones. However, the announcement also highlights various risks associated with drug development and the potential impact on financial outcomes.

LLY

Aug 14, 2023

Lilly Completes Acquisition of Sigilon Therapeutics Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The...

Eli Lilly and Company has successfully completed its acquisition of Sigilon Therapeutics, enabling continued research and development of encapsulated cell therapies for type 1 diabetes. The acquisition includes an upfront cash payment and contingent value rights tied to performance milestones. Following the merger, Sigilon's common stock will be delisted, transitioning it into a wholly-owned subsidiary of Lilly. However, Lilly acknowledges inherent risks and uncertainties associated with drug development and the integration process.

LLY

Aug 9, 2023

Lilly Completes Acquisition of DICE Therapeutics Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The...

Eli Lilly and Company has finalized its acquisition of DICE Therapeutics, significantly enhancing its immunology portfolio with new oral therapeutic candidates. The tender offer for DICE shares concluded successfully, with a substantial majority of shares being tendered. The integration of DICE's innovative approaches into Lilly is expected to advance its development of treatments for chronic immunological diseases. However, there are inherent risks related to the acquisition that may impact financial results and operational stability.

LLY

Aug 8, 2023

Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579.0 million from the ...

Eli Lilly and Company reported its financial results for Q2 2023, showcasing a remarkable 28% increase in revenue compared to Q2 2022, largely driven by the strong performance of Mounjaro and its Growth Products. Net income also saw a robust increase of 85%, reaching $1.76 billion, alongside significant investments in research and development. The company highlighted promising developments in its pipeline, including breakthroughs in Alzheimer's disease and obesity treatments. Looking forward, Lilly anticipates multiple product launches by year's end to enhance patient access worldwide.

LLY

Aug 4, 2023

Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy...

Eli Lilly announced that their targeted therapy Retevmo has shown to improve progression-free survival in patients with advanced RET fusion-positive non-small cell lung cancer, compared to standard chemotherapy plus a PD-1 inhibitor. This finding is based on the LIBRETTO-431 study, which met its primary endpoint according to an independent data monitoring committee. Retevmo is now officially recognized as a more effective treatment option in this specific patient population, although it is associated with various serious adverse events that require monitoring and caution. Detailed results are set to be shared at upcoming medical forums and peer-reviewed journals.

LLY

Jul 27, 2023

Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies Eli Lilly and Company (NYSE: LLY) announced results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related...

Eli Lilly announced positive results from two Phase 3 trials for tirzepatide, focusing on weight loss in adults with obesity or overweight. In the SURMOUNT-3 trial, participants achieved a mean weight loss of 26.6% over 84 weeks, while the SURMOUNT-4 trial reported a similar loss of 26.0% over 88 weeks. Both studies demonstrated superiority of tirzepatide compared to placebo, with a favorable safety profile mainly consisting of mild to moderate gastrointestinal-related adverse events. The findings suggest tirzepatide could redefine weight management solutions as a chronic treatment.

LLY

Jul 25, 2023

Lilly Announces Extension of Tender Offer to Acquire DICE Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...

Eli Lilly and Company has announced an extension of its tender offer to acquire DICE Therapeutics, raising the expiration date to August 8, 2023. The offer price remains at $48 per share, with 20.05% of shares already tendered as of July 24, 2023. The acquisition is anticipated to close in the third quarter of 2023, although it remains subject to customary closing conditions, including necessary antitrust clearance. Lilly has also disclosed potential risks that could affect the completion of the acquisition.

LLY

Jul 25, 2023

Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023. Lilly will also conduct a...

Eli Lilly and Company (NYSE: LLY) has scheduled the announcement of its second-quarter 2023 financial results for August 8, 2023. The company will also conduct a conference call on that day to discuss its financial performance further. Investors and the public can access the call via a live webcast, with a replay available afterward, enhancing investor communication and transparency.

LLY

Jul 17, 2023

Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their...

Eli Lilly recently presented results from its Phase 3 TRAILBLAZER-ALZ 2 trial, showing that donanemab significantly slows cognitive decline in early symptomatic Alzheimer's disease. The study found that nearly 50% of participants did not experience clinical progression after one year, with additional benefits observed in those at earlier disease stages. FDA submission for traditional approval has been completed, with a decision expected by the end of the year. However, there are risks associated with the treatment, including potential adverse effects such as ARIA.

LLY

Jul 14, 2023

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage...

Eli Lilly aims to acquire Versanis Bio, focusing on improving treatments for cardiometabolic diseases. Versanis is known for its clinical-stage asset, bimagrumab, which is being tested for efficacy in reducing fat mass while maintaining muscle composition. The deal, worth up to $1.925 billion, hinges on the achievement of certain developmental and sales milestones. Lilly anticipates the acquisition will leverage its expertise alongside Versanis's innovative approaches, potentially benefiting patients significantly. However, the acquisition is subject to typical closing conditions and faces inherent uncertainties.

LLY

Jul 11, 2023

Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast...

Eli Lilly and Company will host a webcast on July 17, 2023, during the Alzheimer's Association International Conference. The event will focus primarily on the results of the donanemab TRAILBLAZER-ALZ 2 clinical trial, providing important updates in the Alzheimer's disease landscape. Attendees will be able to access the live audio webcast and later view a replay on Lilly's Investor website.

LLY

Jul 6, 2023

New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published...

Eli Lilly's oncology unit, Loxo@Lilly, announced that the New England Journal of Medicine has published results from the BRUIN Phase 1/2 trial, which evaluated pirtobrutinib's efficacy and safety in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a BTK inhibitor. The study included 247 patients and reported a 73.3% overall response rate. While the safety profile appeared consistent with earlier studies, patients had high rates of treatment-emergent adverse events. The findings suggest potential for pirtobrutinib as a significant option for this difficult-to-treat patient group.

LLY

Jun 29, 2023

Lilly to Acquire Sigilon Therapeutics Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon,...

Eli Lilly and Company has entered a definitive agreement to acquire Sigilon Therapeutics for approximately $34.6 million in cash plus contingent value rights that could increase the total consideration. This acquisition is expected to enhance Lilly's capabilities in developing innovative cell therapies for type 1 diabetes, leveraging their past partnership with Sigilon. Completion of the acquisition is subject to certain conditions and is anticipated to close in the third quarter of 2023.

LLY

Jun 26, 2023

Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment ...

Eli Lilly announced promising phase 2 results for retatrutide, an investigational obesity treatment, achieving a mean weight reduction of 17.5% at 24 weeks. In follow-up results, a significant 24.2% reduction was observed at 48 weeks. Alongside effective weight management, improvements in key cardiometabolic measures were reported. The company aims to explore retatrutide's potential further in phase 3 trials, focusing on obesity and related complications.

LLY

Jun 26, 2023

Lilly Declares Third-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding...

Eli Lilly and Company has announced a quarterly dividend of $1.13 per share for the third quarter of 2023, payable on September 8, 2023. This dividend reflects the company's strong performance and commitment to возвращение value to shareholders. Additionally, Lilly’s ongoing initiatives in biotechnology and medicine aim to address significant global health challenges, including diabetes and Alzheimer's disease.

LLY

Jun 24, 2023

Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10...

Eli Lilly's tirzepatide, evaluated in the SURMOUNT-2 trial, demonstrated significant efficacy in weight reduction for adults with obesity and type 2 diabetes, achieving a mean reduction of 15.7% at 15 mg. The drug met both co-primary and key secondary endpoints, showing improvements in various cardiometabolic health indicators. Despite the promising results, gastrointestinal side effects were noted as common adverse events. Lilly has submitted the treatment for FDA approval, anticipating action by the end of 2023.

LLY

Jun 23, 2023

Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1)...

Eli Lilly recently announced promising phase 2 results for orforglipron, a novel oral GLP-1 receptor agonist aimed at weight management and type 2 diabetes. The study showed significant weight reductions, achieving an average decrease of up to 14.7% after 36 weeks of treatment. Notably, gastrointestinal side effects were observed but were generally mild-to-moderate. Lilly plans to advance orforglipron into phase 3 trials for further evaluation of its efficacy and safety.

LLY

Jun 21, 2023

US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and...

The U.S. FDA has approved Jardiance (empagliflozin) for treating type 2 diabetes in children aged 10 years and older, marking a critical advancement in pediatric diabetes care. This approval addresses the growing issue of type 2 diabetes among youth, with the prevalence nearly doubling in the past two decades. Results from the DINAMO trial demonstrated a significant reduction in A1c levels in young patients when Jardiance was added to their treatment regimen. However, caution is advised as the medication is not suitable for those with type 1 diabetes or severe kidney issues.

LLY

Jun 20, 2023

Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and obesity portfolio and pipeline at the American Diabetes...

Eli Lilly and Company (NYSE: LLY) will present 40 abstracts at the American Diabetes Association's 83rd Scientific Sessions from June 23 to 26, focusing on diabetes and obesity treatments. This includes findings from the SURMOUNT-2 trial on tirzepatide for weight management and promising phase 2 results from investigational drugs retatrutide and orforglipron. Lilly emphasizes its commitment to enhancing treatment options for chronic diseases with its diverse pipeline. Presentations will cover the efficacy and safety profiles of these medications, highlighting their potential roles in managing obesity and type 2 diabetes.

LLY

Jun 20, 2023

Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch Tap the Cap Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association® (ADA) and Adam Duvall, American professional baseball player, ...

Eli Lilly and the American Diabetes Association have launched the 'Tap the Cap' campaign to raise awareness about affordable insulin access for those living with diabetes. The campaign emphasizes Lilly's monthly insulin cap of $35 and includes contributions to ADA summer camps for children with diabetes. It features Adam Duvall, a professional baseball player and type 1 diabetes advocate, who shares his personal experiences with the condition. The initiative seeks to educate insulin users on affordability options amidst the growing concern for insulin accessibility.

LLY

Jun 20, 2023

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE...

Eli Lilly and Company has announced a definitive agreement to acquire DICE Therapeutics for $48 per share, totaling approximately $2.4 billion. The acquisition aims to leverage DICE's DELSCAPE technology platform to enhance Lilly's drug discovery in immunology. The deal has been approved by both companies' boards and is expected to close in Q3 2023, pending customary conditions including antitrust clearance. DICE's Board of Directors recommends that shareholders tender their shares as part of this acquisition process.

LLY

Jun 16, 2023

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant...

Eli Lilly announced the results of the CHALLENGE-MIG clinical trial, comparing its migraine treatment Emgality to Nurtec ODT. Although Emgality showed robust efficacy, it did not surpass Nurtec on the primary endpoint of reducing monthly migraine days. Nonetheless, it performed better on key secondary endpoints and maintained a safety profile consistent with previous studies. The results highlight the ongoing efforts in migraine research and the need for accessible treatment options.

LLY

Jun 2, 2023

Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy ...

Eli Lilly presented new data on Verzenio (abemaciclib) and Jaypirca (pirtobrutinib) at the 2023 ASCO Annual Meeting. The analyses from the Phase 3 monarchE trial revealed that Verzenio maintains its efficacy in treating high-risk early breast cancer across different age groups, and quality of life scores were comparable to endocrine therapy alone. Updated findings from the Phase 1/2 BRUIN trial of Jaypirca showed durable efficacy in relapsed or refractory mantle cell lymphoma without newly identified safety concerns. Both treatments are demonstrating promise in their respective indications.

LLY

May 30, 2023

Lilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly...

Eli Lilly and Company (NYSE: LLY) is set to participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12-13, 2023. Anat Ashkenazi, the company's executive vice president and chief financial officer, will take part in a fireside chat on June 12 at 4:20 p.m. Eastern time. Investors and interested parties can access a live audio webcast of this event on Lilly's Investor website. A recording will be available for approximately 90 days following the presentation.

LLY

May 22, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's...

Eli Lilly and Company (NYSE: LLY) has released its latest Environmental, Social and Governance (ESG) report, highlighting significant progress towards sustainability goals. The report details a 20% reduction in greenhouse gas emissions and notable improvements in healthcare access for patients in resource-limited settings. Additionally, the company has intensified its commitment to diversity, equity, and inclusion by increasing its spending with Black-owned businesses significantly. Lilly's sustainability strategy aims to support its mission of delivering innovative medicines globally.

LLY

May 18, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in...

Eli Lilly and Company's phase 2a trial of peresolimab for rheumatoid arthritis has shown promising results, with the treatment meeting its primary efficacy endpoint. This trial, published in The New England Journal of Medicine, indicates a novel approach in stimulating the PD-1 pathway for RA treatment. The study found that peresolimab maintained similar rates of adverse events compared to placebo, suggesting a favorable safety profile. Despite the positive outcomes, there are cautions about the drug's regulatory approval and future consistency in results.

LLY

May 11, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the...

Loxo@Lilly, the oncology division of Eli Lilly and Company, announced details of presentations regarding its oncology portfolio at the upcoming 2023 European Hematology Association Annual Meeting. Key studies focus on the company's drug Jaypirca (pirtobrutinib), including its effectiveness in treating patients with B-cell malignancies. The provided data reflects findings from the BRUIN Phase 1/2 trial and highlight important safety information related to the treatment. The event is set to take place from June 8 to 11 in Frankfurt, Germany, both in-person and virtually.

LLY

May 9, 2023

Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting ...

Eli Lilly and Company has announced an additional $50 million allocation to its Social Impact Venture Capital Portfolio, raising the total to $300 million. This initiative is intended to foster healthcare solutions that benefit historically marginalized communities while addressing racial injustice. The portfolio includes support for venture capital firms focused on healthcare accessibility in low- and middle-income countries. Lilly's commitment since 2020 has also included funding directed towards diverse and innovative healthcare approaches for underserved populations.

LLY

May 9, 2023

Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative...

Eli Lilly and Company announced new investigational data for mirikizumab as a treatment for moderately to severely active ulcerative colitis. The data includes interim Phase 2 results from pediatric patients and a new analysis from adult Phase 3 studies. The findings suggest mirikizumab may significantly improve quality of life, particularly in relation to bowel urgency symptoms. Additionally, upcoming Phase 3 studies in pediatric patients are anticipated to commence later this year, addressing a critical unmet need in this demographic.

LLY

May 3, 2023

Lilly to Participate in Bank of America Securities 2023 Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson,...

Eli Lilly and Company (NYSE: LLY) is set to participate in the Bank of America Securities 2023 Healthcare Conference taking place from May 9-11, 2023. Patrik Jonsson, an executive vice president, will be featured in a fireside chat scheduled for May 10 at 1 p.m. Eastern time. The company is providing an audio webcast of the event, which will also have a replay available for 90 days on their investor website.

LLY

May 3, 2023

Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed ...

Eli Lilly announced positive outcomes from the Phase 3 TRAILBLAZER-ALZ 2 study of donanemab, which significantly slowed cognitive decline in early Alzheimer's disease patients by 35% compared to placebo. The study met its primary and all secondary endpoints, demonstrating substantial clinical benefits. The company plans to expedite regulatory submissions in hopes of receiving FDA approval soon. Despite the promising results, the treatment is associated with risks such as ARIA-related side effects and infusion reactions, which are typical of amyloid-targeting therapies.

LLY

May 2, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli...

Eli Lilly and Company has announced a $500,000 grant initiative aimed at providing educational assistance for Deferred Action for Childhood Arrivals (DACA) recipients in Indiana. This funding will support four local nonprofits focused on improving access to post-high school education for the state's immigrant population. Indiana currently does not offer DACA students in-state tuition, creating financial barriers to higher education. Lilly's efforts are intended to address these challenges and foster a more skilled workforce in the state.

LLY

May 1, 2023

Lilly Declares Second-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding...

Eli Lilly and Company has announced a dividend of $1.13 per share for the second quarter of 2023. This dividend will be paid on June 9, 2023, to shareholders recorded by May 15, 2023. Lilly continues to advance its mission by pioneering new medicines aimed at significant health challenges, impacting millions of lives worldwide. The announcement reflects the company's ongoing commitment to shareholder value and innovative healthcare solutions.

LLY

May 1, 2023

Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were...

Eli Lilly's lebrikizumab shows promising results in recent analyses, with up to 73% of atopic dermatitis patients achieving improved or cleared skin on their face or hands after 16 weeks of treatment. Long-term data indicates sustained effectiveness, as 80% of patients maintained their treatment benefits after one year. These findings highlight lebrikizumab's potential as a significant advancement in managing this challenging skin condition, particularly for visible areas that are often stigmatized.

LLY

Apr 27, 2023

Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1...

Eli Lilly and Company (LLY) reported its first-quarter financial results for 2023, revealing a revenue decline of 11% primarily affected by the loss of COVID-19 antibody sales. However, core business growth, particularly from products like Mounjaro, contributed positively to the company’s performance. While new products are showing promising revenue contribution, overall net income and earnings per share decreased by nearly 29% year-over-year. The company continues to focus on expanding its pipeline and improving affordability for patients.

LLY

Apr 27, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of ...

Eli Lilly announced that tirzepatide, administered at 10 mg and 15 mg doses, demonstrated significant weight loss in adults with obesity or overweight and type 2 diabetes in the SURMOUNT-2 trial. Participants lost up to 15.7% of their body weight, achieving co-primary and secondary objectives. The safety profile was comparable to previous studies, although some gastrointestinal side effects were reported. Lilly intends to complete FDA submission soon with expectations for regulatory approval by late 2023.

LLY

Apr 24, 2023

Lilly to Divest BAQSIMI to Amphastar In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc....

Eli Lilly and Amphastar Pharmaceuticals have entered an agreement for Amphastar to acquire the worldwide rights to BAQSIMI, the first nasally administered glucagon for severe hypoglycemia in diabetes patients. The deal involves an initial payment of $500 million and potential additional payments based on sales milestones. Lilly aims to enhance patient access to BAQSIMI, while Amphastar seeks to strengthen its diabetes product portfolio. The transaction is expected to close in the 2023 second or third quarter, pending customary closing conditions.

LLY

Apr 17, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new...

Eli Lilly and Company (NYSE: LLY) announced a historic $1.6 billion investment in its manufacturing operations in Boone County, Indiana, which will result in the creation of 200 new highly skilled jobs. This commitment brings Lilly’s total investment to $3.7 billion in the area, highlighting the company’s significant role in the local economy. Additionally, Lilly is pledging $15 million to the Ivy Tech Foundation to establish scholarships aimed at enhancing education and training in pharmaceutical manufacturing. This move underscores Lilly's dedication to innovation and community development in Indiana.

LLY

Apr 13, 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab...

Eli Lilly and Company announced that the U.S. FDA issued a complete response letter for the biologic license application of mirikizumab for ulcerative colitis treatment. The letter cited concerns related to the proposed manufacturing process, but stated there were no issues with the clinical data or safety profile of the drug. Lilly remains confident in the efficacy of mirikizumab and is actively working with the FDA to address the issues mentioned in the response letter.

LLY

Apr 13, 2023

Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a...

Eli Lilly and Company has announced that it will release its first-quarter 2023 financial results on April 27, 2023. Along with the announcement, the company plans to host a conference call at 10 a.m. Eastern time to discuss its financial performance in detail. The call will be accessible to investors, media, and the public via a live webcast, with a replay available afterward.

LLY

Mar 14, 2023

Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer...

Eli Lilly announced that it will present data from its oncology portfolio at the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando. Among the highlights are Phase 1 clinical data for two new inhibitors targeting KRAS G12C and IDH mutations, as well as a Phase 2 study of Verzenio in prostate cancer. Additionally, preclinical data on the binding mechanism of Jaypirca™ will be shared. These presentations underscore Lilly’s continued commitment to advancing cancer therapy options.

LLY

Mar 8, 2023

Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD)...

Eli Lilly announced that solanezumab failed to slow cognitive decline in participants with preclinical Alzheimer's disease in the A4 Study. The treatment did not meet its primary and secondary endpoints, indicating that targeting soluble amyloid beta is ineffective in this patient population. However, Lilly aims to leverage the data generated from this study to inform future Alzheimer's research and enhance clinical trial designs. Other investigational treatments, donanemab and remternetug, are still in Phase 3 trials and target amyloid plaques directly.

LLY

Mar 8, 2023

US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) investigating a...

The FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) to treat children aged 10 years and older with type 2 diabetes. This decision is based on positive results from the DINAMO phase III trial, which showed a significant reduction in A1c levels compared to placebo. If approved, Jardiance would offer a new oral treatment option for this underserved population, as current oral treatments are limited. The safety profile observed in the trial was consistent with previous data for Jardiance.

LLY

Mar 6, 2023

Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study Providing clinics with a coordinated, multifaceted intervention, with assessment of barriers, care pathways and feedback, improved the likelihood...

A recent study presented at the American College of Cardiology Conference revealed that a coordinated, multifaceted intervention improved the adherence to guideline-directed therapies among patients with type 2 diabetes and cardiovascular disease. The study, named COORDINATE-Diabetes, showed that patients receiving the intervention were significantly more likely to be prescribed critical medications compared to those who received usual care. This underscores the importance of collaboration among healthcare providers in managing chronic diseases effectively. Despite significant improvements in medication prescriptions, changes in surrogate outcome measures like blood pressure and cholesterol were not statistically significant.

LLY

Mar 3, 2023

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio®...

Eli Lilly announced that the FDA has approved an expanded indication for Verzenio® (abemaciclib) for high-risk early breast cancer patients. This approval allows for patient selection based solely on nodal status, tumor size, and grade, without needing the Ki-67 score. Supported by data from the four-year monarchE trial, Verzenio added to endocrine therapy demonstrated a 35% reduction in recurrence risk. The update also broadens the drug’s use to include metastatic breast cancer in relevant populations.

LLY

Mar 1, 2023

Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin...

Eli Lilly and Company (NYSE: LLY) has announced a 70% reduction in the list prices of its commonly prescribed insulins and will cap out-of-pocket costs for patients at $35 per month. These measures aim to improve access to insulin for diabetic patients amidst concerns regarding affordability in the healthcare system. Additionally, Lilly intends to launch a public awareness campaign to inform users about these changes and various affordability solutions already in place. This initiative reflects the company's long-standing efforts to address insulin accessibility issues in the U.S. healthcare landscape.

LLY

Feb 21, 2023

Lilly to Participate in Cowen's 43rd Annual Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice ...

Eli Lilly and Company (NYSE: LLY) is set to participate in Cowen's 43rd Annual Health Care Conference on March 6, 2023. Mike Mason, the executive vice president and president of Lilly Diabetes and Obesity, will engage in a fireside chat during the event. A live audio webcast of the presentation will be accessible on Lilly's Investor website, with a replay available for 90 days after the event.

LLY

Feb 7, 2023

Lilly to Participate in SVB Securities Global Biopharma Conference Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023. Ilya Yuffa,...

Eli Lilly and Company (NYSE: LLY) is set to participate in the SVB Securities Global Biopharma Conference on February 16, 2023. Ilya Yuffa, the executive vice president and president of Lilly International, will be featured in a virtual fireside chat. A live audio webcast will be available for attendees, with a replay accessible for 90 days on the company's investor website.

LLY

Feb 3, 2023

Lilly to Participate in Guggenheim Oncology Conference Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023. Jacob Van Naarden, executive vice ...

Eli Lilly and Company is set to participate in the Guggenheim Oncology Conference on February 9, 2023. Key executives, including CEO Jacob Van Naarden, will engage in a fireside chat during the event. An audio webcast will be accessible, providing an opportunity for stakeholders and the public to follow the discussions and insights shared at the conference.

LLY

Feb 2, 2023

Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by...

Eli Lilly and Company reported its financial results for the fourth quarter of 2022, marking a 9% decrease in total revenue year-over-year, primarily driven by lower volume and unfavorable currency impacts. Despite this decline, the company highlighted a 5% increase in revenue when excluding COVID-19 antibody sales. Executives projected significant growth for 2023, with plans to launch several new treatments and an optimistic mid-teen growth target for its core business. Additionally, key growth products contributed to a strong performance, representing a significant portion of the revenue.

LLY

Jan 27, 2023

U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that the U.S. Food and Drug Administration (FDA) approved...

The U.S. FDA has approved Jaypirca™ (pirtobrutinib), developed by Loxo@Lilly, as the first non-covalent BTK inhibitor for adults with relapsed or refractory mantle cell lymphoma after two lines of systemic therapy. This approval is based on data from the BRUIN Phase 1/2 trial, showing a 50% overall response rate among patients previously treated with covalent BTK inhibitors. However, further confirmation of clinical benefit is required to maintain its approval status. Jaypirca provides a new option for patients with limited alternatives, becoming available in the U.S. soon.

LLY

Jan 26, 2023

Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity Eli Lilly and Company (NYSE: LLY) and Direct Relief today announced a new initiative to expand access to medicines in low- and middle-income...

Eli Lilly and Company has partnered with Direct Relief to improve access to medicines in low- and middle-income countries by enhancing cold chain capacity. With a $1.15 million contribution, the initiative aims to install 150 medical-grade refrigeration units at partner facilities across 17 countries. This effort supports the transportation and storage of temperature-sensitive medications, particularly insulin, ensuring they remain effective during delivery. Lilly's commitment to global health includes the broader goal of assisting 30 million people by 2030.

LLY

Jan 24, 2023

Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least 100 new jobs to expand its...

Eli Lilly and Company has announced plans to invest an additional $450 million to expand its manufacturing facility in Research Triangle Park, North Carolina. This investment aims to enhance production capacity for incretin products that treat diabetes and is set to create at least 100 new jobs when fully operational in 2027. Lilly has committed around $4 billion to manufacturing expansions in the state since 2020, with plans to begin initial production this year. The company is focused on meeting the growing demand for its medicines and continues to prepare for potential new product launches in various therapeutic areas.

LLY

Jan 20, 2023

US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which is...

The U.S. FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) as a treatment for chronic kidney disease (CKD). This decision is based on positive results from the EMPA-KIDNEY trial, which showed significant reductions in the risk of kidney disease progression and cardiovascular death. Jardiance is now positioned to fulfill a critical treatment gap for the approximately 37 million U.S. adults suffering from CKD. The drug was previously approved for type 2 diabetes but is now being investigated for its effects on kidney health.

LLY

Jan 19, 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the...

Eli Lilly announced that the FDA issued a complete response letter for the accelerated approval of donanemab, a treatment for early symptomatic Alzheimer's disease due to insufficient data on patient exposure. Despite this setback, the Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with data expected in Q2 2023 to support a traditional approval application. Lilly is committed to collaborating with the FDA to expedite the availability of this treatment for patients.

LLY

Jan 19, 2023

Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a...

Eli Lilly and Company (NYSE: LLY) has announced that it will release its fourth-quarter 2022 financial results on February 2, 2023. Alongside the announcement, the company will host a conference call at 10 a.m. Eastern time to further discuss its financial performance. Investors and the general public can access a live webcast of the call via Lilly's website, with a replay available afterward.

LLY

Jan 4, 2023

Lilly to Participate in the J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. David A. Ricks, Lilly's...

Eli Lilly and Company (NYSE: LLY) is scheduled to participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. CEO David A. Ricks will engage in a fireside chat at 6:45 p.m. Eastern time. Interested parties can access a live audio webcast on Lilly's Investor website, with a replay available for 90 days post-event.

LLY

Dec 22, 2022

Lilly and ProQR to Expand RNA Editing Collaboration Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration...

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS and LEIDEN, Netherlands and CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and

LLY

Dec 14, 2022

Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today a collaboration to deliver a sustainable supply of high-quality, affordable human...

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries INDIANAPOLIS and CAIRO , Dec. 14, 2022 /PRNewswire/

LLY

Dec 13, 2022

Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for...

INDIANAPOLIS , Dec. 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2023 financial guidance, highlighted by expected volume-based revenue growth and increased investments to maximize future value. The company will review potential key events for th

LLY

Dec 12, 2022

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2...

Pirtobrutinib demonstrates activity across covalent BTK inhibitor pre-treated B-cell malignancies and multiple patient subgroups INDIANAPOLIS , Dec. 12, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY ), today announced updated clinical dat

LLY

Dec 12, 2022

Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the...

INDIANAPOLIS , Dec. 12, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is

LLY

Dec 7, 2022

Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average...

INGELHEIM, Germany and RIDGEFIELD, Conn. and INDIANAPOLIS , Dec. 7, 2022 /PRNewswire/ -- The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with Jardiance ® (empagliflozin)

LLY

Dec 6, 2022

Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology Eli Lilly and Company (NYSE: LLY) today announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio® (abemaciclib) in...

The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolute improvement in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS) rates of 6.4% and 5.9% at four years,

LLY

Dec 1, 2022

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition...

INDIANAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS ). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential fir

LLY

Nov 30, 2022

Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in...

- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm ® (aducanumab-avwa)-treated patients at 6 months - Donanemab reduced brain amyloid plaque levels vs. baseline by 65.2% compared with 17.0% for Aduhe

LLY

Nov 30, 2022

Lilly and Akouos Announce Expiration of Akouos Tender Offer Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding ...

INDIANAPOLIS and BOSTON , Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Akouos, Inc. (NASDAQ: AKUS ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 pe

LLY

Nov 29, 2022

Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call...

INDIANAPOLIS , Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's

LLY

Nov 21, 2022

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the...

INDIANAPOLIS , Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022 , in Sa

LLY

Nov 16, 2022

Lilly to Participate in Evercore ISI HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden,...

INDIANAPOLIS , Nov. 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 , 2022. Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman , M.D., chief med

LLY

Nov 7, 2022

Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared...

The platform consists of three key components – the Tempo Smart Button ® ; a compatible app, TempoSmart™; and a prefilled insulin pen, Tempo Pen ® – which work together to deliver personalized guidance for adults with diabetes. The Smart Button was cleared by the U.S. Food and Dr

LLY

Nov 4, 2022

Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with ...

- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice - Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any caus

LLY

Nov 3, 2022

Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase...

INDIANAPOLIS , Nov. 3, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY ), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting t

LLY

Nov 1, 2022

Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially...

INDIANAPOLIS , Nov. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the third quarter of 2022. "Lilly delivered another solid quarter with pipeline advancements across the portfolio, continued growth of key products, and impre

LLY

Oct 27, 2022

Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration Purdue University and Eli Lilly and Company (NYSE: LLY) are establishing an innovative new pharmaceutical manufacturing scholarship program and have...

Scholarships will prioritize students from underrepresented groups, who have overcome disadvantages or are first generation to attend college Research collaboration aims to develop new methods for delivering therapies to patients INDIANAPOLIS and WEST LAFAYETTE, Ind. , Oct. 27,

LLY

Oct 19, 2022

Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022. Lilly will also conduct a...

INDIANAPOLIS , Oct. 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the co

LLY

Oct 18, 2022

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision...

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approxima

LLY

Oct 17, 2022

Lilly Declares Fourth-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding...

INDIANAPOLIS , Oct. 17, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on Dec. 9, 2022 to shareholders of record at t

LLY

Oct 6, 2022

Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...

The Fast Track designation accelerates tirzepatide's path to U.S. FDA submission for the treatment of adults with obesity, or overweight with weight-related comorbidities INDIANAPOLIS , Oct. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S.

LLY

Sep 21, 2022

FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has granted approval to Retevmo® (selpercatinib, 40 mg...

Tumor-agnostic data supporting approval demonstrated an overall response rate (ORR) of 44% across multiple tumor types FDA simultaneously grants traditional approval in adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, as detec

LLY

Sep 8, 2022

Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials New detailed results from Eli Lilly and Company's (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational...

INDIANAPOLIS , Sept. 8, 2022 /PRNewswire/ -- New detailed results from Eli Lilly and Company's (NYSE: LLY ) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients w

LLY

Sep 7, 2022

Lilly Announces Details of Presentations at ESMO Congress 2022 Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be presented at ...

INDIANAPOLIS , Sept. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from studies of Verzenio ® (abemaciclib) and Retevmo ® (selpercatinib) will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, to be held Septemb

LLY

Aug 31, 2022

Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, ...

INDIANAPOLIS , Aug. 31, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13 , 2022. Anat Ashkenazi, Lilly's senior vice president and chief financial officer, will participate in a fi

LLY

Aug 25, 2022

Lilly to Participate in Citi's 17th Annual BioPharma Conference Eli Lilly and Company (NYSE: LLY) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022. Daniel Skovronsky, M.D., Ph.D.,...

INDIANAPOLIS , Aug. 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7 , 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laborato

LLY

Aug 11, 2022

Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the...

- Stephen Fry to retire at the end of 2022 - Eric Dozier named Senior Vice President, Human Resources and Diversity - Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial Officer for Loxo@Lilly INDIANAPOLIS , Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and C

LLY

Aug 8, 2022

Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The...

Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz INDIANAPOLIS , Aug. 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the availability of a new, citrate-free formulation of Taltz ® (ixekizumab)

LLY

Aug 4, 2022

Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue...

INDIANAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the second quarter of 2022. "We had an exciting quarter with the highly anticipated U.S. launch of Mounjaro, the first of potentially five new medicines we in

LLY

Aug 4, 2022

Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time...

INDIANAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties. Investors, media and the general public can

LLY

Jul 21, 2022

Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Lilly will also conduct a...

INDIANAPOLIS , July 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the

LLY

Jun 29, 2022

Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options Eli Lilly and Company (NYSE: LLY) today announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of...

Bebtelovimab continues to maintain neutralization against all known variants of interest and concern INDIANAPOLIS , June 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a modified purchase agreement with the U.S. government to supply an additional 150

LLY

Jun 27, 2022

Lilly Declares Third-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding...

INDIANAPOLIS , June 27, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on Sept. 9, 2022 to shareholders of record at t

LLY

Jun 7, 2022

Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials Eli Lilly and Company (NYSE: LLY) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's...

80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed Data supported both once every two week and once every four week maintenance dosing, with consistent and durable responses

LLY

Jun 6, 2022

New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's (NYSE: LLY) Mounjaro™...

Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study Exploratory analysis showed that Mounjaro achieved A1C and weight targets in less time than injectable sem

LLY

Jun 5, 2022

Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance®...

RIDGEFIELD, Conn. and INDIANAPOLIS , June 5, 2022 /PRNewswire/ -- Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance ® (empagliflozin) was associated with a reduction in risk of hospitaliz

LLY

Jun 4, 2022

Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo In the phase 3 AWARD-PEDS clinical trial from Eli Lilly and Company (NYSE: LLY), Trulicity® (dulaglutide) (at 0.75 mg and 1.5 mg doses) led to...

AWARD-PEDS results presented at ADA's 82nd Scientific Sessions ® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population INDIANAPOLIS , June 4, 2022 /PRNewswire/

LLY

Jun 4, 2022

Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or...

Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's ® 82 nd Scientific Sessions ® and simultaneously published in NEJM INDIANAPOLIS , June 4, 2022 /PRNewswire/ -- Detailed results from Eli Lilly and Company'

LLY

Jun 3, 2022

Lilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. Anne White,...

INDIANAPOLIS , June 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 , 2022. Anne White, senior vice president and president, Lilly Neuroscience, and Mark Mintun , senior vice pre

LLY

May 26, 2022

Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical...

INDIANAPOLIS , May 26, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 . The data include new analyse

LLY

May 25, 2022

Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at...

INDIANAPOLIS , May 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County . These new f

LLY

May 24, 2022

Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks ...

Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids INDIANAPOLIS , May 24, 2022 /PRNewswire/ -- In Eli Lilly and Company's (NYSE: LLY ) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded t

LLY

May 23, 2022

Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its...

INDIANAPOLIS , May 23, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast w

LLY

May 16, 2022

Lilly to Participate in UBS Global Healthcare Conference 2022 Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 24, 2022. Michael Mason, senior vice president,...

INDIANAPOLIS , May 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the UBS Global Healthcare Conference on Tuesday, May 24 , 2022. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in a fireside chat at 8:30 a.m., Eastern

LLY

May 13, 2022

FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP...

Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint Mounjaro represents the first new cla

LLY

May 11, 2022

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and Drug Administration (FDA) has approved OLUMIANT®...

OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support INDIANAPOLIS , May 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced

LLY

May 6, 2022

Mary Lynne Hedley Elected to Lilly Board of Directors The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022. As a member ...

INDIANAPOLIS , May 6, 2022 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY ) has elected Mary Lynne Hedley , Ph.D., as a new member, effective May 15, 2022 . As a member of Lilly's board, she will serve on both the Science & Technology Committee and the

LLY

May 3, 2022

Lilly to Participate in Bank of America Securities 2022 Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022. Daniel Skovronsky, M.D., Ph....

INDIANAPOLIS , May 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11 , 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Lab

LLY

May 2, 2022

Lilly Declares Second-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding...

INDIANAPOLIS , May 2, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on June 10, 2022 to shareholders of record at th

LLY

Apr 28, 2022

Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and...

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpoint INDIANAPOLIS , April 28, 2022 /PRNewswire/ -- Tirzepatide (5 mg, 10 mg,

LLY

Apr 28, 2022

Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022...

INDIANAPOLIS , April 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the first quarter of 2022. "Lilly delivered another quarter of volume-driven revenue growth led by key products and anticipates 2022 to be an exciting year

LLY

Apr 20, 2022

Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes compared to men. A deeper look reveals...

RIDGEFIELD, Conn. and INDIANAPOLIS , April 20, 2022 /PRNewswire/ -- Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes compared to men. A deeper look reveals that among Black and Latina women with heart failure, negative

LLY

Apr 19, 2022

Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022. Lilly will also conduct a...

INDIANAPOLIS , April 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail th

LLY

Apr 11, 2022

Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical...

Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key secondary endpoints INDIANAPOLIS , April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent

LLY

Apr 1, 2022

Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg...

INDIANAPOLIS , April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Retevmo (

LLY

Mar 26, 2022

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies Adults with severe alopecia areata (AA) who took OLUMIANT® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% ...

New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today In the pooled 52-week analysis, patients at baseline had a mean Severity of Alopecia Tool (SALT) score of 85.5 (85.5% scalp hair loss, or 14.5% scalp hair coverage); severe AA is defined as hav

LLY

Mar 26, 2022

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity...

Lebrikizumab rapidly improved skin and itch symptoms in four weeks INDIANAPOLIS , March 26, 2022 /PRNewswire/ -- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75 * ) at 16 weeks

LLY

Mar 24, 2022

Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for...

INDIANAPOLIS , March 24, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab in

LLY

Mar 16, 2022

Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a...

OXFORD, United Kingdom and RIDGEFIELD, Conn. and INDIANAPOLIS , March 16, 2022 /PRNewswire/ -- The EMPA-KIDNEY trial, evaluating the effect of Jardiance ® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial's Indep

LLY

Mar 8, 2022

Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be presented ...

INDIANAPOLIS , March 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from the pirtobrutinib and Verzenio ® (abemaciclib) development programs will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, April 8

LLY

Mar 3, 2022

Lilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022. Patrik Jonsson, Lilly...

INDIANAPOLIS , March 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15 , 2022. Patrik Jonsson, Lilly senior vice president, president of Lilly Immunology and Lilly USA , and chief customer

LLY

Mar 1, 2022

Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance®...

RIDGEFIELD, Conn. and INDIANAPOLIS , March 1, 2022 /PRNewswire/ -- Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared wit

LLY

Feb 28, 2022

Lilly to Participate in Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on Tuesday, March. 8, 2022. Anat Ashkenazi, Lilly senior vice...

INDIANAPOLIS , Feb. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cowen Health Care Conference on Tuesday, March. 8, 2022. Anat Ashkenazi, Lilly senior vice president and chief financial officer, will participate in a virtual fireside chat at

LLY

Feb 24, 2022

US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and...

RIDGEFIELD, Conn. and INDIANAPOLIS , Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer I

LLY

Feb 22, 2022

Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site Eli Lilly and Company (NYSE: LLY) today announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700...

INDIANAPOLIS , Feb. 22, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. Thi

LLY

Feb 18, 2022

Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission...

INDIANAPOLIS , Feb. 18, 2022 /PRNewswire/ -- Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission at 12 weeks compared to patients taking placebo in Eli Lilly and Company's (NYSE: LLY

LLY

Feb 16, 2022

Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people...

INDIANAPOLIS , Feb. 16, 2022 /PRNewswire/ -- Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people diagnosed with breast cancer understand these risk factors. In recognizing the need fo

LLY

Feb 11, 2022

Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates...

INDIANAPOLIS , Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY ) announced today.

LLY

Feb 10, 2022

Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug...

INDIANAPOLIS , Feb. 10, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million . The U.S. government will accept the doses of bebtel

LLY

Feb 10, 2022

Cynthia Cardona Elected as President of the Lilly Foundation The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY), has elected Cynthia Cardona as...

INDIANAPOLIS , Feb. 10, 2022 /PRNewswire/ -- The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY ), has elected Cynthia Cardona as its president. Additionally, Lilly has selected Cardona to serve as senior director o

LLY

Feb 3, 2022

Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. Lilly had a remarkable year of...

INDIANAPOLIS , Feb. 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced financial results for the fourth quarter and full year of 2021 today. "Lilly had a remarkable year of growth and pipeline success in 2021, despite the continued hardships from the pandemic,"

LLY

Feb 2, 2022

UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and...

NEW YORK and INDIANAPOLIS , Feb. 2, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 20

LLY

Feb 1, 2022

Lilly to Participate in Guggenheim Oncology Conference Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9, 2022. Jake Van Naarden, CEO of Loxo...

INDIANAPOLIS , Feb. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9 , 2022. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology and David Hyman , M.D., chief medical o

LLY

Jan 28, 2022

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in...

INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) today announced updates on the Phase 3 development program for OLUMIANT ® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus

LLY

Jan 28, 2022

Lilly announces $1 billion investment in new manufacturing facility in North Carolina Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord,...

INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina . The brand-new facility will utilize the latest technology to manufacture

LLY

Jan 20, 2022

Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022. Lilly will also...

INDIANAPOLIS , Jan. 20, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to furth

LLY

Jan 6, 2022

Lilly to Participate in the J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, Jan. 11, 2022. David A....

INDIANAPOLIS , Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, Jan. 11 , 2022. David A. Ricks, Lilly's chairman and CEO, will participate in a virtual fireside chat at 4:30 p

LLY

Jan 6, 2022

Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research,...

INDIANAPOLIS and EDMONTON, AB , Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central an

LLY

Dec 21, 2021

Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with...

INDIANAPOLIS , Dec. 21, 2021 /PRNewswire/ -- Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's (NYSE: LLY ) third pivotal P

LLY

Dec 15, 2021

Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong ...

INDIANAPOLIS , Dec. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At an investment community meeting today,

LLY

Dec 14, 2021

Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022 Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at...

INDIANAPOLIS , Dec. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety

LLY

Dec 13, 2021

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today...

INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), and Foghorn Therapeutics Inc. (Nasdaq: FHTX ), today announced a strategic collaboration to create novel oncology medi

LLY

Dec 13, 2021

Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15 percent increase in its quarterly dividend and declared a dividend for ...

INDIANAPOLIS , Dec. 13, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share on outstanding common stock. The divid

LLY

Dec 12, 2021

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the...

INDIANAPOLIS , Dec. 12, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leu

LLY

Dec 10, 2021

Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to...

INDIANAPOLIS and SHANGHAI , Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.

LLY

Dec 9, 2021

New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show...

INDIANAPOLIS , Dec. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or immediate need for a bowel movement – is the seco

LLY

Dec 3, 2021

Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together...

INDIANAPOLIS , Dec. 3, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to <12 years old, Eli Lilly

LLY

Dec 1, 2021

Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting Eli Lilly and Company (NYSE: LLY) announced today that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021, from 9 a.m....

INDIANAPOLIS , Dec. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021 , from 9 a.m. to 4 p.m., Eastern time . Earlier that day, the company will announce its initial fin

LLY

Nov 18, 2021

Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients Today, Eli Lilly and Company (NYSE: LLY) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head...

INDIANAPOLIS , Nov. 18, 2021 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the pre

LLY

Nov 17, 2021

Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30, 2021. Daniel...

INDIANAPOLIS , Nov. 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 , 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lill

LLY

Nov 11, 2021

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance®...

RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 11 , 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance ® (empagliflozin) 10 mg, which is being investigated as a potential ne

LLY

Nov 11, 2021

Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care Today Eli Lilly and Company (NYSE: LLY) announced the five winners of the inaugural Leonard Award, which commemorates the 100th anniversary of the...

INDIANAPOLIS , Nov. 11, 2021 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY ) announced the five winners of the inaugural Leonard Award, which commemorates the 100 th anniversary of the discovery of insulin by recognizing diverse champions dedicated to advancing diabetes

LLY

Nov 9, 2021

Lilly to Participate in Wolfe Research Virtual Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18, 2021. Jacob Van Naarden, ...

INDIANAPOLIS , Nov. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18 , 2021. Jacob Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology; Mark Mintun , senior vi

LLY

Nov 9, 2021

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis OLUMIANT® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA)...

INDIANAPOLIS , Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously pu

LLY

Nov 5, 2021

Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and...

RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 5, 2021 /PRNewswire/ -- Jardiance ® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left

LLY

Nov 4, 2021

Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present...

INDIANAPOLIS , Nov. 4, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that study investigators will present data from the pirtobrutinib development program at the American Society of Hematology

LLY

Nov 2, 2021

Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19 Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration...

INDIANAPOLIS , Nov. 2, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the tr

LLY

Nov 1, 2021

Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van...

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations . A replay of the presentation will be available on this same website for approximately 90 days. About Eli Lilly

LLY

Oct 28, 2021

Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter...

INDIANAPOLIS , Oct. 28, 2021 /PRNewswire/ -- Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY ) Verzenio ® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology . These OS data, while immature, have been p

LLY

Oct 26, 2021

Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. Lilly demonstrated strong performance again this...

INDIANAPOLIS , Oct. 26, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced financial results for the third quarter of 2021 today. "Lilly demonstrated strong performance again this quarter. Revenue attributable to our newer medicines grew more than 35 percent and r

LLY

Oct 19, 2021

Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all...

INDIANAPOLIS , Oct. 19, 2021 /PRNewswire/ -- Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from

LLY

Oct 18, 2021

Lilly Declares Fourth-Quarter 2021 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding...

INDIANAPOLIS , Oct. 18, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on December 10, 2021 to shareholders of record

LLY

Oct 14, 2021

Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of...

INDIANAPOLIS , Oct. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for th

LLY

Oct 13, 2021

FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine...

INDIANAPOLIS , Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY ) Verzenio ® (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult pa

LLY

Oct 12, 2021

Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021. Lilly will also conduct a...

INDIANAPOLIS , Oct. 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail th

LLY

Oct 7, 2021

Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data ...

INDIANAPOLIS , Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EOR

LLY

Oct 4, 2021

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification...

RIDGEFIELD, Conn. and INDIANAPOLIS , Oct. 4, 2021 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced the launch of CRMSynced ™ , an educational initiative that uses gamification to encourage healthcare professionals (HCPs) to prioritize a

LLY

Oct 1, 2021

At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as...

INDIANAPOLIS , Oct. 1, 2021 /PRNewswire/ -- Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as demonstrated in new results from Eli Lilly and Company's (NYSE: LLY ) Phase 2 study. Sympt

LLY

Sep 30, 2021

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and...

INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT ® (baricitinib) 4-mg was superior to placebo in

LLY

Sep 30, 2021

Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in...

INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a conti

LLY

Sep 30, 2021

Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 ...

INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 diabetes in an MRI sub-study of Eli Lilly and Company's (NYSE: LLY ) phase 3 SURPASS

LLY

Sep 29, 2021

Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women Today, Eli Lilly and Company (NYSE: LLY) and Susan G. Komen®, the world's leading breast cancer organization, launched a new multiyear program to...

INDIANAPOLIS and DALLAS , Sept. 29, 2021 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) and Susan G. Komen ® , the world's leading breast cancer organization, launched a new multiyear program to address breast cancer health disparities experienced by Black women in the

LLY

Sep 28, 2021

FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new indication for...

INDIANAPOLIS , Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new indication for ERBITUX ® (cetuximab injection) in combination with BRAFTOVI ® (encorafenib), marketed by

LLY

Sep 28, 2021

Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options Eli Lilly and Company (NYSE: LLY) will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1,...

INDIANAPOLIS , Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1, 2022 , effectively bringing the list price down to 2008 levels. The new list price w

LLY

Sep 27, 2021

New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine ...

INDIANAPOLIS , Sept. 27, 2021 /PRNewswire/ -- New data from Eli Lilly and Company's (NYSE: LLY ) monarchE study for an investigational use of Verzenio ® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth

LLY

Sep 24, 2021

Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar...

INDIANAPOLIS , Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is voluntarily recalling lot D239382D, Expiration April 2022 , of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the consum

LLY

Sep 21, 2021

Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19 Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of...

INDIANAPOLIS , Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in patients aged 1

LLY

Sep 21, 2021

Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its...

INDIANAPOLIS , Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding debt securities. Holders of notes subject to the tender offer who validly tend

LLY

Sep 21, 2021

Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059 Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its...

INDIANAPOLIS , Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities. Lilly also announced that it has removed the previously

LLY

Sep 16, 2021

Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg...

INDIANAPOLIS , Sept. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for

LLY

Sep 15, 2021

Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized...

INDIANAPOLIS , Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, Lilly will su

LLY

Sep 13, 2021

Lilly to Present New Data from Oncology Portfolio at ESMO Congress New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab)...

INDIANAPOLIS , Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY ) Verzenio ® (abemaciclib), Retevmo ® (selpercatinib) and CYRAMZA ® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021,

LLY

Sep 13, 2021

Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021. Patrik...

INDIANAPOLIS , Sept. 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28 , 2021. Patrik Jonsson, senior vice president, president of Lilly Immunology and Lilly USA , and chie

LLY

Sep 9, 2021

Lilly Prices First Sustainability Bond to Advance Global ESG Strategy Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and...

INDIANAPOLIS , Sept. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to medicines, improve lives and communities, e

LLY

Sep 9, 2021

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance® (empagliflozin) as an investigational treatment...

RIDGEFIELD, Conn. and INDIANAPOLIS , Sept. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance ® (empagliflozin) as an investigational treatment for adults with heart failure with preserved ejection fraction (

LLY

Sep 7, 2021

Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal...

INDIANAPOLIS , Sept. 7, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the " Tender Cap ") of specified series of its outstanding debt securities. Pursua

LLY

Sep 7, 2021

Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to Type 1 Diabetes Camps Initiative Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M. and Harry B. Helmsley Charitable Trust to...

INDIANAPOLIS , Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M. and Harry B. Helmsley Charitable Trust to promote greater access to care and resources and to inspire confidence for children li

LLY

Sep 3, 2021

Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021....

INDIANAPOLIS , Sept. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14 , 2021. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in

LLY

Aug 31, 2021

Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference Eli Lilly and Company (NYSE: LLY) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi,...

INDIANAPOLIS , Aug. 31, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual firesid

LLY

Aug 27, 2021

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance® (empagliflozin) showed an impressive 21% relative risk...

RIDGEFIELD, Conn. and INDIANAPOLIS , Aug. 27, 2021 /PRNewswire/ -- Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance ® (empagliflozin) showed an impressive 21% relative risk reduction for the composite primary endpoint of cardiovascular

LLY

Aug 25, 2021

Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on ...

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of

LLY

Aug 25, 2021

Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) announced today that Carolyn R. Bertozzi, Ph.D., has resigned from her role as an...

INDIANAPOLIS , Aug. 25, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) announced today that Carolyn R. Bertozzi , Ph.D., has resigned from her role as an independent director of Lilly's board. Her resignation is in connection with Lilly's entry

LLY

Aug 18, 2021

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus...

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 18, 2021 /PRNewswire/ -- Jardiance ® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduc

LLY

Aug 17, 2021

Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience and immunology business units. These...

INDIANAPOLIS , Aug. 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced executive leadership changes and the creation of neuroscience and immunology business units. These changes will increase Lilly's focus on introducing breakthrough new medicines to mill

LLY

Aug 16, 2021

FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY) rapid-acting insulin, Lyumjev®...

INDIANAPOLIS , Aug. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY ) rapid-acting insulin, Lyumjev ® (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in a

LLY

Aug 16, 2021

Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic...

INDIANAPOLIS , Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY ) ADvocate 1 an

LLY

Aug 3, 2021

Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2021. We delivered strong performance this quarter,...

INDIANAPOLIS , Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2021. "We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies. We accel

LLY

Aug 3, 2021

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the...

INDIANAPOLIS , Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or ext

LLY

Jul 29, 2021

Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses ...

INDIANAPOLIS , July 29, 2021 /PRNewswire/ -- Today at the Alzheimer's Association International Conference © (AAIC © 2021), Eli Lilly and Company (NYSE: LLY ) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaq

LLY

Jul 29, 2021

FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency...

INDIANAPOLIS , July 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdes

LLY

Jul 29, 2021

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive...

INDIANAPOLIS and SAN DIEGO , July 29, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercializatio

LLY

Jul 22, 2021

Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021. Lilly will also conduct a...

INDIANAPOLIS , July 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the

LLY

Jul 16, 2021

Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the...

INDIANAPOLIS , July 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug applicati

LLY

Jul 15, 2021

Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3, ...

INDIANAPOLIS and PHOENIX , July 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab in participant

LLY

Jul 14, 2021

Lilly Announces Acquisition of Protomer Technologies Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies ( Protomer ), a private biotech company. Protomer's...

INDIANAPOLIS , July 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the acquisition of Protomer Technologies ("Protomer"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize mo

LLY

Jul 6, 2021

Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to...

RIDGEFIELD, Conn. and INDIANAPOLIS , July 6, 2021 /PRNewswire/ -- The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance ® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or ho

LLY

Jun 26, 2021

Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of...

INDIANAPOLIS , June 26, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE: LLY ) SURPASS-1 monotherapy clinical trial eva

LLY

Jun 24, 2021

Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize...

INDIANAPOLIS , June 24, 2021 /PRNewswire/ -- In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY ) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking an

LLY

Jun 24, 2021

Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY)...

INDIANAPOLIS , June 24, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY ) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designatio

LLY

Jun 17, 2021

Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a...

INDIANAPOLIS , June 17, 2021 /PRNewswire/ -- Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a variety of reasons, and even fewer receive a diagnosis and take the treatment they need.

LLY

Jun 15, 2021

Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)...

The study, which is the first head-to-head clinical trial comparing two medications targeting CGRP, is a multi-site, randomized, double-blind, double-dummy, parallel-group Phase 4 study in patients who meet the International Classification of Headache Disorders (ICHD) criteria fo

LLY

Jun 14, 2021

Lilly to Participate in Guggenheim Biopharma Strategy Series Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on...

INDIANAPOLIS , June 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021 . Daniel Skovronsky , M.D., Ph.D

LLY

Jun 11, 2021

Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at...

INDIANAPOLIS , June 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual 81st Scientific Sessions. The webcast wil

LLY

Jun 4, 2021

Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer,...

INDIANAPOLIS , June 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57 th Ann

LLY

Jun 3, 2021

Lilly to Participate in Goldman Sachs Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice...

INDIANAPOLIS , June 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White , senior vice president and president, Lilly Oncology and Jake Van Naarden , CEO, Loxo Oncology at Lilly,

LLY

Jun 3, 2021

Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021 To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY) presented data on unmet needs in migraine from...

INDIANAPOLIS , June 3, 2021 /PRNewswire/ -- To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY ) presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the Americ

LLY

Jun 1, 2021

Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of...

INDIANAPOLIS , June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz ® (ixekizumab) among patients with axial spondyloarthritis (axSpA). These results

LLY

May 19, 2021

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology...

INDIANAPOLIS , May 19, 2021 /PRNewswire/ -- New data from across Eli Lilly and Company's (NYSE: LLY ) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021 . The data include new analyses of Verzenio ® (a

LLY

May 13, 2021

Lilly to Participate in UBS Global Healthcare Virtual Conference Eli Lilly and Company (NYSE: LLY) will participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021. Anat Ashkenazi, senior ...

INDIANAPOLIS , May 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 . Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual fireside c

LLY

May 11, 2021

Lilly and MiNA Therapeutics Announce saRNA Research Collaboration Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research...

INDIANAPOLIS and LONDON , May 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activ

LLY

May 6, 2021

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic...

INDIANAPOLIS , May 6, 2021 /PRNewswire/ -- With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY ) signed strategic international agreements with four companies – DexCom, Inc., Glooko Inc., myDiabby Healthcare and

LLY

May 5, 2021

Lilly to Participate in Bank of America Securities 2021 Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael...

INDIANAPOLIS , May 5, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021 . Michael Mason , senior vice president, president of Lilly Diabetes, will participate in a virtua

LLY

May 4, 2021

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19...

INDIANAPOLIS , May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pa

LLY

May 4, 2021

Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe Eli Lilly and Company (NYSE: LLY) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in ...

INDIANAPOLIS , May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in key areas during the company's Sustainability Webcast today at 10:30 am ET . In additi

LLY

May 4, 2021

Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of...

INDIANAPOLIS , May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world

LLY

May 3, 2021

Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity Eli Lilly and Company (NYSE: LLY) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over...

INDIANAPOLIS , May 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over the next five years. The Fund launched in March 2020 with $75 million raised against a

LLY

May 3, 2021

Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization The board of directors of Eli Lilly and Company (NYSE: LLY) (the Board ) has declared a dividend for the second quarter of 2021 of $0.85 per share...

INDIANAPOLIS , May 3, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) (the "Board") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on June 10, 2021 to shareholders of

LLY

Apr 27, 2021

Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021. $ in millions, except per share data First Quarter ...

INDIANAPOLIS , April 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2021. Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele

LLY

Apr 23, 2021

Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz® (ixekizumab) demonstrated greater success in ...

INDIANAPOLIS , April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY ) Taltz ® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderat

LLY

Apr 23, 2021

OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE:...

INDIANAPOLIS , April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY ) and Incyte's (NASDAQ: INCY ) OLUMIANT ® (baricitinib) 2-mg tablet taken once dai

LLY

Apr 20, 2021

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy...

INDIANAPOLIS , April 20, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia ar

LLY

Apr 16, 2021

Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. Eli Lilly and Company (NYSE: LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for...

INDIANAPOLIS , April 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made this request due to the evolving variant l

LLY

Apr 13, 2021

Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer Eli Lilly and Company (NYSE: LLY) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information ...

INDIANAPOLIS , April 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information and digital officer. Rau succeeds Aarti Shah , whose planned retirement was announc

LLY

Apr 12, 2021

Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies ...

INDIANAPOLIS , April 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of Lilly's planne

LLY

Apr 11, 2021

Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo®...

INDIANAPOLIS , April 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo ® (selpercatinib) demonstrated encouraging antitumor activity and safety across RET fusion

LLY

Apr 8, 2021

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once...

INDIANAPOLIS , April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet st

LLY

Apr 6, 2021

Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021. Lilly will also conduct a...

INDIANAPOLIS , April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the

LLY

Apr 1, 2021

Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an...

INDIANAPOLIS , April 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to sustainability efforts in the areas of Enviro

LLY

Mar 31, 2021

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better...

RIDGEFIELD, Conn. and INDIANAPOLIS, March 31, 2021 /PRNewswire/ -- Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better outcomes than those whose HCPs do not, while the top barrier to more c

LLY

Mar 29, 2021

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from...

INDIANAPOLIS and SAN FRANCISCO and LONDON , March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), Vir Biotechnology, Inc. (NASDAQ: VIR ) and GlaxoSmithKline plc (LSE/NYSE: GSK ) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk ad

LLY

Mar 17, 2021

Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021 Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio® (abemaciclib) in...

INDIANAPOLIS , March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone recep

LLY

Mar 16, 2021

Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3...

INDIANAPOLIS , March 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of

LLY

Mar 13, 2021

Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson...

INDIANAPOLIS , March 13, 2021 /PRNewswire/ -- Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY ) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 ( AD/PD™ 2021 ) held virtually March 9-14, 2021 and published simulta

LLY

Mar 10, 2021

Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating ...

INDIANAPOLIS , March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together signifi

LLY

Mar 10, 2021

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR) Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021...

INDIANAPOLIS , March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually A

LLY

Mar 9, 2021

Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer's &...

INDIANAPOLIS , March 9, 2021 /PRNewswire/ -- New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY ) at the upcoming virtual International Conference on Alzheimer's & Parkinson Diseases ™ 2021 (AD/PD ™ 2021), March 9-14, 2021 . Lilly will present detailed

LLY

Mar 9, 2021

Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of two executive committee members and the naming of their successors in...

INDIANAPOLIS , March 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the upcoming retirement of two executive committee members and the naming of their successors in the company's manufacturing operations and ethics and compliance organizations. Myles

LLY

Mar 8, 2021

Lilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021. Patrik Jonsson, senior vice ...

INDIANAPOLIS , March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 . Patrik Jonsson , senior vice president, president of Lilly USA and chief customer officer, will participate in

LLY

Mar 8, 2021

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ( Biolojic ), a biotechnology company that computationally designs functional antibodies,...

INDIANAPOLIS and TEL AVIV , March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will

LLY

Mar 5, 2021

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data...

INDIANAPOLIS , March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clini

LLY

Mar 5, 2021

EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...

"Today's CHMP recommendation is another important milestone in our efforts to extend access to antibody therapies for patients with COVID-19 around the world, providing a pathway for more EU countries to enable use of potentially life-saving treatments for COVID-19. In addition,

LLY

Mar 4, 2021

Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults...